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 BOOST THE DSICOVERY OF MRP7/ABCC10 SUBSTRATES AND INHIBITORS: 
ESTABLISHMENT OF NEW IN VITRO AND IN SILICO MODELS 
 
JINGQUAN WANG 
ATP-binding cassette (ABC) transporters are responsible for the efflux of structurally 
distinct endo- and xenobiotics energized by ATP hydrolysis. MRP7/ABCC10 belongs to 
the 10th member of subfamily C and responsible for mediating MDR against a series of 
chemotherapeutic drugs such as taxanes, epothilones, Vinca alkaloids, anthracyclines and 
epipodophyllotoxins.  
Establishment of new in silico and in vitro models for MRP7 substrates/inhibitors 
prediction  
Considering the limited knowledge of MRP7, we established a homology model based on 
bovine MRP1 cryo-EM models. The final model was used for protein global motion 
analysis and docking analysis. Before docking, potential drug binding pockets were 
identified and evaluated. Next, MRP7 substrates and inhibitors were docked into drug 
binding pockets. We found that docked inhibitors and substrates formed separate clusters, 
from which a substrate binding region and an inhibitor binding region were proposed. 
This homology protein model enables the docking analysis of potential MRP7 ligands for 
future studies. Moreover, we established a new SKOV3/MRP7 cell line which exhibits 
similar drug resistance profile as the previously established HEK/MRP7 cell line. This 
new cell line is valuable for MRP7 substrates and inhibitors discovery. Last but not the 
least, we established a novel machine learning model named Mrp7Pred for large-scale 
MRP7 substrates/inhibitors prediction. The model was also deployed as a web server and 
  
is freely available to users in http://www.mrp7pred.com. We successfully identified 2 
substrates and 4 inhibitors from 70 FDA-approved drugs using Mrp7Pred. 
New synthetic agents targeting MRP7 and overcomes MRP7-medited MDR 
Previously, we identified two synthetic compounds, CMP25 and CP55, as potent ABCB1 
and ABCG2 inhibitors. Here we found these two compounds also significantly reversed 
the MDR mediated by MRP7. Both compounds significantly sensitized MRP7-
overexpressing HEK/MRP7 cells to paclitaxel and vincristine. Western blotting indicates 
that neither CMP25 nor CP55 alters MRP7 expression level. Immunofluorescence 
showed that the subcellular localization of MRP7 was not altered by these two 
compounds. However, intracellular accumulation of [3H]-paclitaxel and [3H]-vincristine 
were significantly increased while the efflux was significantly reduced when co-
administered with CMP25 or CP55. Hydrophobic interactions were predicted as the 
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The ABC transporter superfamily 
Since the first discovery of the membrane transport protein P-glycoprotein (P-gp) 
or ATP-binding cassette (ABC) transporter B1 (ABCB1) in drug resistant cancer cells in 
the mid-1970s, numerous studies have been published regarding ABC transporters and 
their potential therapeutic roles in cancer and other diseases (1). ABC transporters are the 
best known for mediating multidrug resistance (MDR) and lead to failure of 
chemotherapy in cancer. Besides, studies also revealed their importance in cancer beyond 
efflux pumps such as regulating tumor promoting signaling pathways (2,3). ABC 
transporter superfamily is composed of 7 subfamilies, namely ABCA to ABCG, which in 
human derive at least 48 members with different functions. Among the 48 members, 
approximately 13 ABC transporters (including ABCA2/3, ABCB1/2/5, 
ABCC1/2/3/4/5/6/10 and ABCG2) are directly relevant to chemoresistance by mediating 
the efflux of chemotherapeutic agents (4), which subsequently leads to reduced 
intracellular concentration of drugs in cancer cells and deteriorated therapeutic efficacy. 
Due to the critical roles ABC transporters played in human cancers, overcoming cancer 
MDR by targeting the ABC transporters has been prioritized since the development of 
first generation of ABCB1 inhibitor, although clinical trials using these inhibitors have 
not yet achieved satisfactory results (5). Developing novel inhibitors of ABC transporters 
and repurposing approved drugs as ABC transporter modulators are still the major target 
in this field (6). During recent years, numerous synthesized compounds as well as FDA-
approved therapeutic drugs have been discovered as potent ABC transporter modulators 
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in vitro and in vivo, which further extended our knowledge and provided candidates that 
have the potential for clinical applications. 
Multidrug resistance proteins (MRPs) 
As mentioned before, increased efflux of multiple chemotherapeutic agents can 
cause chemotherapy failure due to decreased intracellular drug level and thus limited 
efficacy (2). Such a phenomenon is termed multidrug resistance, or MDR. ATP-binding 
cassette (ABC) transporters have been well studied as one of the major factors that 
mediate MDR in cancer, since many members in the ABC transporter superfamily are 
responsible for the efflux of structurally distinct anticancer drugs (7). Among all ABC 
transporters, the ABCC subfamilies have 13 members (ABCC1 to ABCC13), 9 of which 
were characterized as MRPs (Table 1).(8).  
 









































ABCC6 chr16 p13.11 1503 165 Long MRP Basolateral 
MRP
7 




ABCC11 ABCC11 chr16 q12.1 1382 170 Short MRP Apical, basolateral 
MRP
9 
ABCC12 ABCC12 chr16 q12.1 1356 100 Short MRP Not clear 
 
Structurally, MRPs share structural features including multiple transmembrane 
domains (TMDs, also referred to as “membrane spanning domains” or “MSDs”) and 
nucleotide binding domains (NBDs) for ATP binding and hydrolysis. The number of 
TMDs may differ between MRPs: MRPs 4, 5, 8 and 9 are relatively shorter MRPs since 
they lack the additional N-terminal TMD0, while the other members (MRPs 1, 2, 3, 6 and 
7) are “long” MRPs with TMD0. As a feature found uniquely in only 5 MRPs, the 
function of TMD0 remains unclear.  
Although MRPs have different structures and amino acid compositions, they 
share a similar mechanism of transport driven by ATP hydrolysis. Unlike P-gp, which 
extrudes mostly xenobiotics, MRPs are responsible for the extrusion of both endo- and 
xenobiotics, indicating its important role in regulating physiological processes as well as 
cancer MDR (2,9). Table 2 summarizes the substrate specificities of MRPs. In a recent 
structural study of MRP1, the authors revealed the potential transport mechanism and 
how substrate binding promotes the transport cycle (10). The cryo-EM structure of 
bovine MRP1 supported a unique substrate recruitment mechanism which is different 
from P-gp. In brief, substrates of MRP1 are likely to be recruited directly from the 
cytoplasm, whereas P-gp binds substrates from the inner leaflet of the lipid bilayer 
(11,12). 
Multidrug resistance protein 7 (MRP7/ABCC10) 
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In 2001, multidrug-resistant protein 7 (MRP7), also known as ABCC10, was 
discovered as a new member of the ABCC subfamily (13). MRP7, with a mass of 171-
kDa, contains three TMDs and two NBDs. MRP7 lacks a conserved N-linked 
glycosylation site at the N-terminus compared to MRP1-MRP3, and MRP6 which have a 
similar structural architecture to MRP7 (14). The expression of the MRP7 gene is strong 
in a variety of tissues, including pancreas, kidneys, brain, lung, ovary, testis, prostate, 
colon, leukocytes and skin (15).  
MRP7 is a lipophilic anion transporter involved in detoxification, transporting 
GSH conjugates and glucuronate conjugates (16). Previous reports revealed that MRP7 is 
a drug resistance factor for various anti-cancer drugs including paclitaxel, docetaxel, 
vincristine, and vinorelbine (17–20). MRP7 also confers resistance to nucleoside-based 
agents such as gemcitabine, fluoropyrimidines, and a novel class of natural product 
agents known as epothilone B (21).   
Numerous studies showed that MRP7 expression levels can be a valuable 
prediction biomarker for the outcome of a variety of cancers. The Hopper-Borge’s group 
determined that MRP7 is highly expressed in HER2+ and ER+ human breast cancer cell 
lines BT474, MCF7, and T47D, while the triple-negative breast cancer cell lines BT549, 
HS578T, and MDAMB-231 expressed the lowest levels of MRP7 (22). Moreover, higher 
expression of MRP7 was detected in HER2+ and ER+ breast cancer tumor specimens 
(22). It was found that tumors grew more quickly in Abcc10-/- mice  harboring tumor 
xenografts than wild-type mice; however, in the Abcc10+/+ mice, the tumors displayed 
increased apoptosis, blood vessel formation, and lung metastasis (22). The results 
indicated that cell lines derived from Abcc10+/+ mice showed active migration compared 
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to cell lines derived from Abcc10-/- tumors. A previous study showed that the expression 
of the MRP7 protein is significantly associated with overall survival of colorectal cancer 
patients undergoing 5-FU-based chemotherapy  (23). A low level of MRP7 protein 
expression was observed in colorectal cancer patients with shorter overall survival. This 
indicated that low MRP7 expression is predictive of a poor prognosis in colorectal cancer 
and MRP7 expression is worthy of future validation for its prognostic value. Zhu et al., 
determined the prognostic significance of ABCC subfamily members in gastric cancer 
using KaplanMeier survival analysis (24). The results showed that MRP7 was 
significantly associated with both negative and positive HER2 status. High expression of 
MRP7 indicated a poor prognosis. Thus, MRP7 may be a significant potential prognosis 
biomarker for gastric cancer (24). The association of MRP7 expression with paclitaxel 
sensitivity was tested in non-small cell lung cancer (NSCLC) cells. The results revealed 
that high expression levels of MRP7 led to a significantly lower paclitaxel sensitivity in 
17 human NSCLC cell lines (25). Thus, MRP7 expression is a predictive biomarker for 
paclitaxel resistance in NSCLC. Apart from the association with cancer, a recent study 
indicated that MRP7 expression is primarily correlated with regular growth of the cell 
population instead of cell cycle progression (26). Overall, it is very important to deepen 
our understanding in overcoming MRP7-mediated cancer drug resistance.   
Machine learning and drug discovery 
 Before the significant advancement of machine learning and deep learning 
algorithms, researchers have been implementing ligand-based and structure-based models 
for high-throughput screening of drug candidates. Discovering ABC transporter 
modulators was also one of the major tasks in this field. Conventional methods include 
 6 
Hansch analysis, pharmacophore modeling, linear and non-linear regression. Later, with 
the development of machine learning techniques, supervised and unsupervised artificial 
neural networks have been widely applied in ABC transporter ligand prediction (27). In 
this section, several most popular machine learning algorithms used in drug design and 
discovery were introduced.  
Support vector machine (SVM) 
Support vector machine (SVM) is one of the most popular supervised non-linear 
classification models in machine learning. It was first proposed by Vapnik in 1992, used 
a supervised machine learning approach based on a statistical learning theory called 
Vapnik Chervonenkis Theory. In brief, SVM is a marginal classifier, which works by 
finding the optimal hyperplane to separate data with different labels at maximum margin 
(28). Different from fundamental marginal classifiers, SVM innovatively involved the 
kernel functions (such as linear, polynomial and radial basis function kernel) to transform 
original data into higher dimensional spaces, so that it has non-linear classification 
capabilities (29). The term “support vector” stands for a set of data points that locates on 
the margins. Given a labelled dataset: 
(𝑥!, 𝑦!), … , (𝑥", 𝑦"), 𝑥# ∈ ℝ	𝑎𝑛𝑑	𝑦# ∈ {−1, 1} 
where xi is a feature vector and yi is the class label. Here the label was set 1 and -1 for 
reasons explained below. Then the optimal hyperplane is defined as: 
𝐷(𝑥) = 𝑤𝑥$ + 𝑏	 
where w is the learnable weight vector and b is the learnable bias that SVM will learn via 
the training process. Then the margin could be expressed as a minimal 𝜏 that holds: 
𝑦#𝐷(𝑥#)
||𝑤|| ≥ 𝜏 
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Then we can apply a constraint 𝜏9|𝑤|9 = 1. Here, maximizing the margin 𝜏 is equivalent 




, which subject to constraints: 
|𝑦#|	(𝑤𝑥#$ + 𝑏) ≥ 1 
This problem could be solved by introducing the Lagrange multipliers: 
𝑄(𝑤, 𝑏, 𝛼) =
1
2 9




Here 𝛼#′𝑠 are Lagrange multipliers. By differentiating and substituting w, we get  








subject to ∑ 𝑦#𝛼# = 0, 𝛼# ≥ 0, 𝑖 = 1,…𝑛	"#)!  




+ 𝐶∑ 𝜉## , 𝑤ℎ𝑒𝑟𝑒	𝑦#(𝑤𝑥#$ + 𝑏) ≥ 1 − 𝜉# . Here when 𝜉#′𝑠 are not zero, vectors are 




Figure 1. SVM illustration. Positive and negative were displayed as blue circles and red 
squares, respectively. Support vectors were represented as solid shapes. The hyperplane 
was represented as green solid line. 
 
Figure 1 showed an illustration of SVM classifier. The reason why SVM could 
solve non-linear problems is the introduction of kernel functions (30). The main idea of 
kernel functions is to add additional dimensions to the training data and convert the 
problem to a linear problem in higher dimensional space. The most common kernel 
functions include linear kernel, Gaussian kernel and polynomial kernel. The 
representation of each kernel is given below: 
𝐾,#"-./(𝒙𝟏, 𝒙𝟐) =< 𝒙𝟏, 𝒙𝟐 > 
𝐾2.344#."(𝒙𝟏, 𝒙𝟐) = exp	(−𝛾9|𝒙𝟏 − 𝒙𝟐|9
() 
𝐾56,7"68#.,(𝒙𝟏, 𝒙𝟐) = (< 𝒙𝟏, 𝒙𝟐 > +1)9 
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Linear kernel is the standard scaler product. The Gaussian kernel is also known as RBF 
kernel, where 𝛾 is the inverse-width parameter which is related to the number of support 
vectors. In polynomial kernel, the parameter d is the degree of polynomial function (31). 
 Various SVM models for drug discovery has been developed over the past 
decade, and SMV has shown promising performance in compound activity prediction and 
non-linear structure-activity relationship modeling (32). However, intuitive accessibility 
is one of the major shortcomings of SVM which makes it hard to illustrate the chemical 
terms (33).  
 Random forest 
 Random forest is another supervised learning algorithm that could be applied to 
classification and regression (34). In brief, it is a combination of decision tree predictors 
where each tree predicts based on a random independent vector derived from the feature 
vectors (35). Random forest has been widely used in different fields including drug 
discovery (Figure 2) (36).  
 
Figure 2. An illustration of random forest method. 
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 Random forest is composed of B decision trees {𝑇!(𝑋), … , 𝑇:(𝑋)} where 𝑋 =
{𝑥!, … , 𝑥8}, an m-dimension vector of features (molecular descriptors, fingerprints, or 
other quantitative properties). Then the forest outputs B independent predictions {𝑌![ =
𝑇!(𝑋), … , 𝑌:\ = 𝑇:(𝑋)}. Outputs of the forest are the aggregated prediction of all trees. In 
classification problems, the final output is produced by the majority of trees (voting); in 
regression problems, the final output is the average of individual tree predictions (37). 
The first step of the training procedure is drawing a bootstrap sample (i.e. random 
sampling, with replacement, n batches) from the training data. Then for each bootstrap 
batch, grow a decision tree based on a random subset of the whole feature vector. Here 
the maximum size of subsets is a tunable parameter. Trees are grown till the maximum 
size is reached (no splits are available) and leave without pruning. The training stops until 
B trees were successfully generated. If we use all features to grow each tree, the 
algorithm is then same as bagging (38). The reasons why random forest is efficient are: 1) 
the feature subset could be very small, thus each tree could be quickly split and grown; 2) 
there is no pruning for individual trees in random forest (39).  
Boosting and the out-of-bag performance estimation 
Boosting is another ensemble learning algorithm based on decision trees (40). In 
brief, boosting is a sequence of trees, and each tree is trained on all training data. In 
classification problems, data weight will be altered based on whether previous trees 
misclassified the data. In regression problems, trees were grown based on the residual of 
previous trees (41). The final prediction is given by weighted voting or average for 
classification or regression, respectively.  
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In practice, obtaining labeled data could be expensive and time-consuming. Thus 
people use different methods of cross-validation to improve the performance (42). 
Random forest performs cross-validation in a parallel manner with training using the Out-
out-bag (OOB) samples (43). The OOB samples are generated from the sampling 
procedure, where bootstrapping samples were performed where part of the training data 
will not be selected to construct trees. As a result, each tree will have a collection of “left-
out” data—the so-called OOB samples. We can then calculate the error rate (ER, for 
classification) or mean square error (MSE, for regression) from the ensemble prediction 
𝑌];;:(𝑋#): 















It has been shown that the OOB estimation works reasonably well as k-fold cross-
validation. As a result, random forest does not require additional cross-validation (44).  
Supervised learning approaches in drug discovery 
We have introduced the most commonly used supervised learning methods in 
previous sections. Here, we briefly introduce some of the state-of-the-art implementations 
of supervised machine learning algorithms in drug discovery.  
Machine learning models have been heavily involved in the whole drug discovery 
pipelines including target identification and validation, compound screening and lead 
discovery, preclinical development as well as clinical development. Virtual screening 
(VS) is a key step in the process of drug development. Over the past decades, VS has 
evolved from traditional similarity searching to data mining and machine learning 
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approaches, which require large amount of training data. In the past few years, machine 
learning methods have been proved to boost the drug discovery techniques such as 
docking analysis. For example, Sato et al. showed SVM and RF models outperformed 
GlideScore when at least 5 crystal structures were used for model building (45). Abdo et 
al. proposed a similarity-based VS approach using Bayesian inference network (46). 
Most recently, with the wide availability of graphical processing units (GPUs) that 
greatly accelerate the parallel processing, more complex models, such as deep neural 
network models, were enabled and proved enormous increase in different types of tasks 
(47). Costa et al. built a tree-based classifier to predict genes associated with morbidity 
and druggability. The classifier is trained on protein topology network, metabolic and 
transcriptional interactions (48). In 2017, Pande et al. constructed a large benchmarking 
dataset name MoleculeNet, which contains properties of over 700,000 compounds, which 
has been widely used for benchmarking ML algorithms (49). Recently, researchers at 
AstraZeneca used generative RNNs to design compounds with optimal physiochemical 
properties, which greatly expanded the chemical space (49). In summary, there is a 
tendency to implementat machine learning models in drug-target interaction prediction, 




 In this chapter, we mainly discussed our work in establishing a homology MRP7 
protein model. Some essential background knowledge about homology modeling is 
introduced. The computational methods are described in detail. Overall, we built a MRP7 
homology model and performed molecular docking to validate the structure. We also 
performed molecular dynamics simulation in order to get some insights on the protein 
structural dynamics and functions.  
1.1 Introduction  
 ABCC10/MRP7 was first discovered in about 20 years ago from expressed 
sequence tag databases mining (13) and its transport properties were determined 
subsequently (16). MRP7 was proved to be able to transport multiple types of substrates 
including amphipathic anions such as 17b-estradiol 17-(b-D-glucuronide) (E217bG), 
natural product and derivatives including vinca alkaloids such as vincristine and taxanes 
such as paclitaxel (13,50). In vitro and in vivo studies have suggested that MRP7 was 
responsible for mediating MDR in cancer cells (55–57) and down-regulated MRP7 
expression by targeting its gene expression could enhance cellular sensitivity to 
chemotherapeutic drugs (58). Besides, our group has discovered that MRP7 could be 
functionally regulated by tyrosine kinase inhibitors, phosphodiesterase inhibitors, Raf 
kinase inhibitors, fibroblast growth factor inhibitors and other small molecule drugs, 
leading to reversed MDR in resistant cancer cells (59–64).  
Clinically, MRP7 has been reported to play important roles in acquired MDR and 
the prognosis of certain cancers (51,65). Additionally, MRP7 participates in FOXM-
induced 5-FU resistance in colorectal cancer patients based on the strong correlation 
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between mRNA levels of MRP7 and FOXM in tumor tissues. Furthermore, MRP7 also 
contributes to alteration in intracellular permeation of nevirapine, a non-nucleoside 
reverse transcriptase inhibitor for HIV-1 (66). As a result, further understanding the 
structural features and transportation mechanisms of MRP7 is crucial in increasing the 
survival rate of patients with limited response to chemotherapy due to acquired MDR, as 
well as developing and discovering substrates/modulators to overcome MRP7-mediated 
MDR or decreasing unexpected synergistic toxicity in combinational chemotherapies. 
However, due to the difficulty and cost in obtaining crystal structure of membrane 
protein, no high-resolution structure of human MRP7 is available so far. Previously, the 
cryo-EM structure of bovine MRP1 was reported at 3.1-3.5 Å with inward- and outward-
facing conformations (10,67). Although there are significant differences between MRP1 
and MRP7 in length, size, amino acid sequence and transportation pattern, it still provides 
possibility to construct high-quality homology models of MRP7 via computational 
strategies. Here, we present the homology models of MRP7 combining current 
knowledge of the transporter and the homology modeling methods based on the cryo-EM 
structure of MRP1 in order to: 1) provide a functionally validated human MRP7 
homology model; 2) assess the structural dynamics to identify potential conformational 
changes associated with efflux mechanism; 3) evaluate the behavior of reported 
substrates and modulators of MRP7 by analyzing ligand-protein interactions. Also, extra 
docking simulations were performed using template MRP1 and our homology model to 
further validate that the MRP7 model was not biased towards its templates.  Our study 
will provide rational insights in the drug development or repurposing of MRP7 
modulators. 
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1.2 Computational methods 
Homology modeling of human MRP7 and structure refinement 
Human MRP7 sequence (validated in vitro) was obtained from the publication by 
Hopper et al., where human MRP7 was first discovered and expressed (13). Before 
modeling, a BLAST (basic local alignment search tool) search was performed on PDB by 
using MRP7 protein sequence to find suitable templates. Bovine MRP1 proteins (5UJA) 
were selected as templates considering the identity and resolution.  
A common homology modeling procedure include template alignment, alignment 
adjustment, backbone establishment, loop/side chain prediction and model refinement 
(68). In this study, we used the homology modeling tool Prime provided by Schrodinger 
Suite and visualized in Maestro 11 (Schrödinger, NY). The TMD0 region of MRP7 was 
eliminated before alignment. For each conformation, we created 50 initial models (totally 
100) followed by loop refinement provided in Schrodinger Prime and subjected to quality 
assessment.  
Protein structure assessment 
Generated homology models were evaluated for structure integrity to select the 
one with best quality as judged by Ramachandran favored residues, main chain (M/c) 
bond lengths and bond angles (69), peptide bond planarity (70) and zDOPE (normalized 
Discrete Optimized Protein Energy) score (71). Models with zDOPE score closer to -1.0 
have better quality. The Ramachandran plots, M/c bond lengths/angles and peptide bond 
planarity scores were calculated using PROCHECK (72). Furthermore, the 
QMEANBrane (73) function was applied to better assess transmembrane protein model 
quality. Moreover, QMEAN Z-score (74), ERRAT (75) and MolProbity (76) scores were 
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also calculated. In brief, 1) QMEAN Z-score evaluates how a protein model is in 
agreement with one would expect from experimental structures of similar size. The Z-
score is an integration of global (QMEAN4) and local (QMEAN6) estimates of protein 
quality. Scores closer to zero indicates good structural quality (74). 2) ERRAT scores 
describe the overall quality of a protein model, and higher score indicates better quality. 
The normally accepted range for ERRAT score is > 50 (75). 3) MolProbity score is a 
combined protein quality score which indicates the expected resolution of a possible 
crystal structure of similar quality with tested protein model. Thus lower MolProbity 
score means better quality (76).  
Membrane system and molecular dynamics simulations 
Molecular dynamics simulation was set up and performed as previously described 
with modifications (77). MD simulation system was built using the system builder tool 
provided in Desmond (D.E. Shaw Research, NY). The membrane systems for inward-
facing MRP7 were built separately. A POPC membrane with a predefined TIP3P solvent 
model was established for simulation run. Na+ and Cl- ions were added to neutralize the 
overall charge of the system. The MD simulation was performed in periodic boundary 
conditions (PBC). After a default relaxation protocol, the simulation was performed as 
NpT runs used Nose–Hoover thermostat (78) and Martyna–Tobias–Klein barostat (79) 
methods with isotropic coupling under temperature 300K and pressure 1 bar for 100 ns. 
All MD runs for substructure dynamics analysis were performed independently for 3 
times with different random seeds. All simulations were performed in Ubuntu 18.04 
system with an NVIDIA Tesla P100 GPU. In total 1000 frames were generated and 
subjected to a principal component analysis (PCA) for protein motion pattern prediction 
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using ProDy (80) with in-house python (3.6) scripts and visualized through the NMWiz 
plugin in VMD (81).  
Binding sites identification 
Inward-facing human MRP7 homology model was prepared for binding site 
search as previously described (82,83). In brief, the protein model was preprocessed 
using the Protein Preparation Wizard provided in Schrodinger Suite. Preprocessing steps 
including adding hydrogen atoms, assign bond orders and remove water molecules.  
Binding pockets were identified using SiteMap in Schrodinger Suite and visualized in 
Maestro 11 (Schrödinger, NY).  
Molecular docking 
Docking simulations were performed using AutoDock Vina (1.1.2) (84). The 
protein model and the ligands were modified by adding hydrogen atoms and partial 
charges in AutoDockTools (1.5.4). Docking grid center and size were determined 
according to the binding pocket surrounded by TMDs of MRP7 as well as MRP1 (MRP1 
binding pocket was determined by co-crystalized ligand). Specifically, the docking grid 
was determined by the center coordinates of the predicted binding region. The size of the 
grid box is 30 Å • 30 Å • 30 Å. Each docking run generated 10 poses with the highest 
docking score. All other parameters were set as default. The ligands with highest affinity 
score were exported for visualization and further analysis. The 2D interaction diagram 
was generated by Maestro provided by Schrodinger. The 3D ligand-protein figure was 
generated using UCSF Chimera (v. 1.14). Protein surface was colored by electrostatic 
potential which was calculated by the Coulombic Surface Coloring module. 
Binding pocket characterization 
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Volume of the MRP1 and MRP7 drug binding pockets were calculated using 
SiteMap provided by Schrodinger. For hydrophobicity, we randomly sampled 50-60 
amino acids with docked/crystalized ligands in the center. We used Kyte-Doolittle amino 
acid hydrophobicity scale (KD hydrophobicity score) to calculate the overall 




𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑠𝑎𝑚𝑝𝑙𝑒𝑑	𝑟𝑒𝑠𝑖𝑑𝑢𝑒𝑠 × 	𝐾𝐷	ℎ𝑦𝑑𝑟𝑜𝑝ℎ𝑜𝑏𝑖𝑐𝑖𝑡𝑦	𝑠𝑐𝑜𝑟𝑒 
Statistical analysis 
In this study, we performed statistical analysis to evaluate the difference of 1) 
Molecular dynamics (MD) simulations for sub-structural dynamics analysis; 2) 
comparing the overall RMSD of MRP7 with or without linker 2; 3) Compare the 
hydrophobicity of MRP1 and MRP7 binding pockets. Only trajectories after equilibration 
(50 ns) were considered for statistical analysis. In vitro MTT assay in this study was 
generated from at least three independent triplicated experiments. Results were presented 
as mean ± SD. All pair-wise comparison were performed used one-way ANOVA 
followed by post hoc analysis.  
1.3 Results 
MRP7 homology modeling and structure refinement 
A proper template is determined by multiple factors including sequence identity, 
resolution, functional similarity and sequence alignment, which are essential for 
identifying conserved regions, ligand binding sites as well as structural domains (85). 
Here, the bovine MRP1 (MRP1) with inward-facing (PDB ID: 5UJA) (10) conformations 
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was chosen as modeling template according to the high identity rate among top 
alignments shown in Table 2. The resolution of 5UJA is 3.34 Å.  
Table. 2. Top alignments of MRP7 
PDB 
ID 






6BHU Chain A, Multidrug resistance-
associated protein 1 [Bos taurus] 
1659 34.80% 9.13% 0.0 3.14 
5UJA Chain A, Multidrug resistance-
associated protein 1 [Bos taurus] 
1460 34.88% 9.13% 0.0 3.34 
6C3O Chain E, ATP-binding cassette sub-
family C member 8 [Homo sapiens] 
1581 28.88% 12.88% 0.0 3.90 
5WUA Chain E, SUR1 [Mesocricetus auratus] 1582 30.89% 11.89% 0.0 5.60 
5YKE Chain B, ATP-binding cassette sub-
family C member 8 isoform X2 
[Mesocricetus auratus] 
1582 30.89% 11.89% 0.0 4.11 
5TWV Chain B, ATP-binding cassette sub-
family C member 8 [Cricetus cricetus] 
1590 30.74% 11.89% 0.0 6.30 
 
The final model was shown in Figure 3A. In this study, TMD0 was not included 
in our homology model because the TMD0’s in the templates were not completely 
resolved. Furthermore, previous studies have shown that removal of TMD0 did not affect 
the function of MRP1 protein (86).  According to the sequence alignment, MRP1 and 
MRP7 share similar structural domains including transmembrane domains (TMDs), 
Lasso (L0 linker) and nucleotide-binding domains (NBDs) (Figure 3B-F). The alignment 
contains conserved region of NBDs shared by multiple ABCC members including the 
Walker A, Signature and Walker B (13) (Figure 3D, F). The consensus ATPase sites are 
used for establishing the Mg-ATP system (10).   
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Figure 3. Sequence alignment of MRP1 and MRP7. A) Homology model of 
human MRP7. Key domains were colored as Lasso/Linker 1/Linker 2/Linker 3: green; 
TMD1: blue; TMD2: yellow; NBD1: pink; BND2: red. B) Topological structure of 
human MRP7. Key domains were colored and labeled. C-F) Top: Predicted TMD1 (C) / 
NBD1 (D) / TMD2 (E) / NBD2 (F) structures of human MRP7. Amino acids with high 
identity to template were colored red. Conserved region of NBDs including Walker A/B 
and signature were labelled.  Bottom: Sequence alignment of human MRP7 and bovine 
MRP1. The alignment map was generated using ESPript server (87). 
 Initial models were subjected to a loop refinement procedure provided by 
Schrodinger Prime module. Refined MRP7 models were subjected to a series of 
structural assessment to determine the best model for further studies. Additionally, cryo-
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EM structures of MRP1 were also evaluated with same functions. Top results were 
shown in Table 3. From the results, we found the homology model of MRP7 maintained 
high percentage of residues in Ramachandran favored regions (91.5% for pre-MD and 
91.2% for post-MD). Also, the structures got the most favored main chain layouts 
indicated by the three PROCHECK scores (M/c bond lengths, bond angles and planar 
groups). For both pre-MD and post-MD, most of the residue main chain bond lengths 
(99.5% for pre-MD and 99.1% for post-MD), main chain bond angles (99.4% for pre-MD 
and 98.9% for post-MD) and planar groups (96.4% for pre-MD and 96.0% for post-MD) 
fall in reasonable range. Both crystal structures also got acceptable zDOPE, ERRAT, 
MolProbity and QMEAN Z-scores. The best models were selected and used for MD 
production runs. 
 
Table 3. Structure assessment of top models  
 Ramachandran 





























[up to 0] 
Inward-facing models 
Pre-MD 91.5% 99.5% 99.4% 96.4% -0.64 89.33 3.85 -1.65 
Post-MD 91.2% 99.1% 98.9% 96.0%  -0.79 77.72 3.26 -1.96 
1 : percentage of main chain bonds within the allowed range 
2 : percentage of main chain angles within the allowed range 
3 : percentage of peptide bonds within the allowed planarity range 
 
Domains of MRP7 were determined according to the secondary structure of 
homology models as well as previous reports (13). Although MRP7 belongs to the “long” 
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class of ABCC family, our model does not contain TMD0 domain due to the 
incompleteness of TMD0 structure in both templates (54). Similar to MRP1, TMD1 and 
TMD2 are the major transmembrane domains of MRP7 which forms the binding pocket 
for substrates as well as responsible for the transportation mediated by conformational 
change. The two cytosolic NBDs are responsible for ATP binding and triggering the 
conformational change of the protein.  
When considering the final refined structure after 100 ns MD runs, the 
Ramachandran plots of MRP7 were shown in Figure 4. The overall structure of MRP7 is 
maintained with 91.2% (inward-facing) residues in most favored region (Figure 4). These 
results indicated that the final remained similar quality compared with the initial model 
after 100 ns MD run. The following results and discussion will be based on the MD-
refined model unless otherwise stated.  
 
Figure 4. Ramachandran plots of template crystal structure 5UJA (A), initial model (B), 
MRP7 at the end of 100 ns MD run (C).  
 
 The structure deviation of each MRP7 domain was analyzed separately from the 
MD run using the root mean square deviation (RMSD). The results were displayed in 
Figure 5. Overall, RMSD value of the whole MRP7 model increased in the first 50 ns, 
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reaching a plateau of ~5 Å until the end of the simulation. For RMSDs of separate 
domains, we found that the linker regions (linker 1 between TMD1 and NBD1 and linker 
2 between NBD1 and TMD2) are the major contributors to the total RMSD with final 
RMSD at around 6 Å and relatively higher variation compared to other substructures. 
Linker 3 (Between TMD2 and NBD2) also showed higher equilibrated RMSD compared 
to TMDs and NBDs, but significantly less than linker 1 and 2. TMDs and NBDs 
remained stable eventually at 2.5 – 3.0 Å.  
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Figure 5. Structure deviation of MRP7 substructures in the 100 ns run. A) The RMSDs 
of MRP7 substructures were plotted against time (ns). B) RMSD of MRP7 with linker 
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(black) or without linker (red) in 100 ns MD run. C) RMSF of residues with linker 
(black) or without linker (red) in 100 ns MD run. Residue numbers were shown in x-axis 
and segmented by domains: Red: TMD1; yellow: NBD1; green: TMD2; purple: NBD2. 
Shadow regions indicate standard deviation of 3 independent MD runs. **p < 0.01 via 
one-way ANOVA test compared with non-linker structures. 
 
The cryo-EM structure of MRP1 lacks the linker 2 structure between NBD1 and 
TMD2 probably due to its unstable conformation as well as flexibility. Here, we analyzed 
the role of the de novo linker 2 structure in MRP7. Results showed that linker 2 in MRP7 
contributes positively to the overall stability of the protein (Figure 5B) since the 
equilibrated RMSD of MRP7 without linker 2 is significantly higher than the one with 
linker, although its structure showed intense fluctuation and flexibility according to our 
RMSD data (Figure 5A). Furthermore, in the full system containing POPC membrane, 
missing linker resulted in increased fluctuation of residues (Figure 5C).  
Protein global motions  
The protein global motion was analyzed by PCA function provided in ProDy (80). 
The major motion of protein backbone along specific directions was represented by 
eigenvectors derived from the covariance matrix calculated from consecutive MD 
trajectories (88). In inward-facing MRP7, the NBDs showed higher mobility and a 
pendular motion parallel to the cytoplasm plane and approach each other. Also, the linker 
2 structure showed opposite motion direction in upper and lower segment. Specifically, 
the upper segment which connects to TMD2 moved to the same direction as NBD2, 
while the lower segment moved to the same direction as NBD1. Thus, we infer that the 
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linker absorbs forces generated in intensive movements and caused lagged equilibration 
and less residue fluctuation compared to when no linker 2 was present (Figure 6). The 
TMDs did not show as significant motions as NBDs, but slight oscillatory movements 
along with connected NBDs were observed. Although such movements of TMDs did not 
disturb the arrangement of transmembrane helices, such trend revealed the mechanism of 
initial motions before ATP-binding-triggered ligand affinity change. TMDs were 
connected to NBD1 and NBD2 by linker 1 and linker 3 respectively, which seemed to 
play a similar role in signal propagation between NBDs and TMDs as the SP domains in 
ABCG2 (53).  
 
Figure 6. Global motion pattern of inward-facing MRP7. Red arrows indicate potential 
domain motion direction and distance by PCA analysis. Motions below 1.5 Å were 
hidden. 
 
Binding pockets identification and validation 
To validate the function of our MRP7 model, potential binding pockets were 
identified (Figure 7) for docking analysis (inward-facing). Five potential binding pockets 
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were identified. According to Figure 7A, the yellow pocket embedded in the TMDs was 
the one we are interested in, since its position is consistent with the general binding 
pockets of ABC transporters such as ABCB1 and ABCG2, which also have functional 
binding pockets buried in TMDs. Other binding pockets locate either in TMDs or around 
NBDs. Figure 7B and 7C showed the electrostatic potential of the binding pocket as well 
as the shape. The volume of this pocket is around 1170 Å3, with the Leu549 stands out in 
the center and separates the pocket into two “chambers”.   
 
Figure 7. Predicted binding pockets of inward-facing MRP7. A) All predicted binding 
pockets were displayed with colored solid surface. The pocket marked by the red square 
was the selected binding pockets for docking analysis. B-C) Cytoplasmic (B) and front 
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(C) view of the marked binding pockets. Molecular surface was colored by residue 
electrostatic potential (red: negative; blue: positive). 
 
 Investigations of the transport properties of MRP7 revealed its ability to efflux 
conjugates such as 17b-estradiol-( b-D-glucuronide) (E217 b G) and leukotriene C4 
(LTC4) (16). Also, MRP7 is responsible for mediating the efflux of structurally-distinct 
chemotherapeutic agents including doxorubicin, vincristine, docetaxel, paclitaxel, 
vinblastine (89) and vinorelbine (90). Moreover, our lab has previously discovered 
several small-molecule drugs being MRP7 modulators including nilotinib (61), lapatinib 
(62), cepharanthine (91), sildenafil (92), tariquidar (93), epothilone B and sulfinpyrazone 
(90), which could sensitize MRP7-overexpressing resistant cells to substrate anticancer 
drugs. We also included several drugs that does not show significant interaction with 
MRP7 such as cAMP (16),  siphonellinol D (94), glucuronic acid (16), WHIP-154, SN-
38, 6-MP, 6-TG, 5-FU (89), probenecid (16) and methotrexate (13). Thus, it is 
particularly interesting to investigate the interactions between MRP7 and those drugs. 
Figure 8A showed the docking results of known MRP7 substrates, inhibitors and those do 
not interact with MRP7. The results indicated that our model could reasonably 
distinguish MRP7 modulators (substrates/inhibitors) and non-modulators since the 
modulators (red and blue) have significantly stronger predicted affinity than non-
modulators (grey). 
As mentioned above, it would be important to understand the interaction between 
MRP7 and its modulators. Thus, we first analyzed the docking site by clustering all 
docked ligands. Four separate binding clefts were predicted via EPOSBP software using 
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the docked ligands and predicted binding sites. Mean hydrophobicity was calculated 
based on the residue properties (Figure 8B). The best docking poses of substrates and 
inhibitors formed two clusters which was roughly separated by the Leu549. As shown in 
Figure 8, MRP7 substrates (Figure 8D) tends to bind at the hydrophilic side (yellow 
cluster in Figure 8D) surrounded by Gly299, Gln341, Glu400, Gln407, Leu494, Arg545, 
Pro550, Asn552, Asn553, Arg985, Asp1152, Thr1195, Gln1156 and Gly1196. The 
exceptions were LTC4 and doxorubicin, which have higher binding affinity in different 
sites. For LTC4, the binding pattern is consistent with its bipartite characteristic. The 
polar GSH moiety was stabilized by hydrogen bonds formed with Arg545, Asn552, 
Asn553 and Arg985; while the hydrophobic tail was stabilized by non-polar interactions 
with Leu298, Pro303, Leu1192 and Gly1196 (data not shown). The binding pattern of 
LTC4 with our homology model is similar to that in bovine MRP1, where LTC4 was also 
stabilized in a bipartite pockets (PDB ID: 5UJA). After summarizing the docked ligands, 
we proposed the key amino acids of the binding pocket displayed in Figure 8C. These 
key residues played crucial rules in stabilizing multiple ligands. For example, Lys292 
was responsible for forming hydrogen bonds with docetaxel, doxorubicin, vinorelbine, 
vincristine, E217bG and cepharanthine; Leu549 was involved in stabilizing all docked 
ligands via hydrophobic interactions. Additionally, we found that MRP7 inhibitors tend 
to occupy the hydrophobic cleft (Figure 8E). Among the modulators we analyzed, 
cepharanthine, an herbal extract from Stephania cepharantha, unlike other modulators, 
binds at the polar site. This could be explained by the similarity in the chemical structures 
of cepharanthine as Vinca alkaloid, such as vincristine, which also binds to the polar site.  
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Figure 8. Functional validation of the MRP7 homology model by docking with 
experimentally validated drugs. A) Docking scores of substrates/inhibitors/non-
modulators. Red columns indicate known MRP7 substrates; blue columns indicate known 
MRP7 inhibitors; grey columns indicate drugs that are not interacting with MRP7. *** p 
< 0.005 via one way ANOVA by comparing substrates/inhibitors and negative drugs. 
Docking scores × (-1) were labeled within columns. B) Properties of predicted MRP7 
binding pocket. Blue indicates hydrophobic and red indicates polar. Numbers indicate 
mean hydrophobicity of predicted binding clefts. C) Key residues of predicted binding 
pocket were labeled. Red indicates polar amino acid, blue indicates hydrophobic amino 
acids. Glycine is colored yellow. D) Docked poses of MRP7 substrates in the binding 
pocket. LTC4 and doxorubicin bind to different positions as other substrates. LTC4 was 
colored orange; doxorubicin was colored grey. E) Docked poses of MRP7 inhibitors 
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(displayed as green sticks) in the binding pocket. Inhibitor cepharanthine was colored 
yellow. MRP7 protein surfaces were colored by electrostatic potential (red: negative; 
blue: positive). Abbreviations: LTC: LTC4; TQR: tariquidar; PTX: paclitaxel; VCR: 
vincristine; VNB: vinorelbine; DOC: docetaxel; DOX: doxorubicin; VBL: vinblastine; 
EST: E217bG; LAP: lapatinib; NIL: nilotinib; SUL: sulfinpyrazone; VEM: vemurafenib; 
EPB: epothilone B; CEP: cepharanthine; SIPD: siphonellinol D; GA: glucuronic acid; 
WHIP: WHIP-154; SN: SN-38; PRO: probenecid; MTX: methotrexate. 
 
Comparative analysis with bovine MRP1 
Next, we performed a series of docking simulations to compare the ligand-binding 
patterns of MRP7 and MRP1. Multiple anticancer drugs have been identified as MRP1 
substrates (such as vincristine and methotrexate) or inhibitors (such as probenecid and 
MK571). Previous studies have demonstrated that methotrexate is a substrate of MRP1 
but not MRP7 (13,95). Similarly, paclitaxel is a good substrate of MRP7 but it cannot be 
transported by MRP1 (13,96). In this section, we firstly performed docking analysis using 
LTC4-bound bovine MRP1 structure. Results were shown in Figure 9. In Figure 9A, we 
found that the drug binding pocket of MRP1 was also buried in TMDs. Details of the 
binding pocket were given in Figure 9C. Different from MRP7, MRP1 has a relatively 
smaller binding pockets with volume of around 743 Å3. Figure 9B showed the results of 
docking simulations using known MRP1 substrates/inhibitors and non-modulators. The 
results are consistent with previous in vitro studies, with substrates and inhibitors 
showing higher scores than non-substrate paclitaxel. 
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Figure 9. MRP1-substrate anticancer drugs and modulators docked into MRP1 binding 
pocket. A) Overview of the bovine MRP1 substrate binding pocket. B) Docking scores of 
known MRP1 substrates, inhibitors and negative control drugs. Docking scores × (-1) 
were labeled within columns. Column colors indicate different types (red: substrates; 
blue: inhibitors; grey: negative drugs). Abbreviations: LTC: LTC4; PTX: paclitaxel; 
VCR: vincristine; MTX: methotrexate; PRO: probenecid; MK: MK571. C) Docked poses 
of MRP1 substrates LTC4, vincristine, modulators probenecid, MK571 (yellow sticks). 
Non-substrate paclitaxel was displayed as green sticks. All surfaces were colored by 
electrostatic potential (red: negative; blue: positive). 
 
From Figure 9C, we found that the best docked pose of paclitaxel was actually on 
the edge of the pocket and close to the open end form by TMDs of MRP1. Detailed 
docking complex was shown in Figure 10C and 7D. For MRP7, the paclitaxel was 
stabilized by both polar and hydrophobic interactions. From Figure 10B, we could see 
that 4 hydrogen bonds were formed between paclitaxel and Glu400, Gln407, Asn553, 
Gln1156. The benzene rings were stabilized via hydrophobic interactions with 
Ala334/338, Gly333/337, Gly1196 and Leu1197. For MRP1, in Figure 10D, we could 
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see that paclitaxel was stabilized via two hydrogen bonds with Gln1088 and Tyr440. No 
strong hydrophobic interaction in MRP1 was observed to stabilize the molecule. Thus, it 
is reasonable that paclitaxel has weak or no interaction with MRP1 in actual biological 
systems. 
 The predicted binding poses of methotrexate in MRP1/MRP7 binding pockets 
were shown in Figure 10. In Figure 10E and 7F, the best docking poses of methotrexate 
locates majorly in the two hydrophobic clefts of MRP7, thus less likely to form hydrogen 
bonds with polar residues to stabilize the carboxyl groups as in MRP1 (Figure 10G and 
7H). According to the cryo-EM structure of bovine MRP1, its binding pocket is actually 
composed of a “P-pocket” (polar, formed majorly by Lys332, His335, Leu381, Arg1196, 
Arg1248, Asn1244 and aromatic residues Phe594, Tyr440, Phe385) and an “H-pocket” 
(hydrophobic, formed majorly by Trp1245, Trp553, Met1092, Thr550 and aromatic 
residue Tyr1242) based on the binding pattern of LTC4 (10). Our docking results of 
methotrexate stays consistent with the proposed MRP1 binding pocket. Similar to LTC4, 
methotrexate was stabilized by both polar and hydrophobic interactions. The carboxyl 
groups formed 3 hydrogen bonds with a salt bridge with Arg1196. Moreover, Trp1245 
formed a pi-pi stacking interaction with the ring structure of methotrexate. Although 
several studies have confirmed methotrexate being a good substrate of MRP1 but not 
MRP7, we validated such conclusion in this study to further demonstrate the reliability of 
our homology model. 
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Figure 10. Paclitaxel/methotrexate docked with MRP7 and MRP1 binding pockets. A) 
Paclitaxel docked with the MRP7 binding pocket. Protein surface was colored by 
electrostatic potential. Paclitaxel was displayed as yellow sticks. B) 2-D diagram of 
paclitaxel-MRP7 interactions. Amino acids within 3 Å to paclitaxel were displayed as 
colored bubbles (cyan: polar; green: hydrophobic; red: negatively charged; blue: 
positively charged). Purple lines with arrow indicate hydrogen bonds. Grey circles 
indicate solvent exposure. C) Paclitaxel docked with the MRP1 binding pocket. D) 2-D 
diagram of paclitaxel-MRP1 interactions. E) Methotrexate docked with the MRP7 
binding pocket. Protein surface was colored by electrostatic potential. Methotrexate was 
displayed as purple sticks. F) 2-D diagram of methotrexate-MRP7 interactions. G) 
Methotrexate docked with the MRP1 binding pocket. Methotrexate was displayed as 
magenta sticks H) 2-D diagram of methotrexate-MRP1 interactions. Purple solid lines 
with arrow indicate hydrogen bonds. Purple solid line without arrow indicates salt bridge. 
Green solid line without arrow indicates pi-pi interaction. 
1.4 Discussion 
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Since functional modulation of the ABC transporters is considered a major 
solution in overcoming MDR in cancers (97), understanding the structure-function 
relationship is thus important in the development of novel ABC transporters modulators. 
Moreover, information in drug binding and recognition based on structural analysis is 
necessary in the discovery of potential ABC transporters substrates (98,99)  which will 
provide valuable references for clinicians.  
Considering the lack of MRP7 crystal structure, we constructed two 
conformations of human MRP7 models using homology modeling tools and equilibrated 
by a 100 ns MD run.  Subsequently, the structural dynamics was analyzed based on the 
MD simulation, where we found that linker structures, especially linker 1 and linker 2, 
were the major contributors to the overall structural deviation. In the most recent crystal 
structures of ABC transporters these linker domains were unable to fully determined by 
crystallography (10,67,101), which is collaborated with the flexibility of these particular 
regions in our MD run.  
The structure of the longest linker 2 which connects TMD2 and NBD1, often 
lacks accurate 3D structure in ABC transporter crystal structures. In this study, we 
constructed de novo linker structure and evaluated the role it plays in the structural 
dynamics in MRP7 via RMSD and RMSF analysis. Our results indicated that the linker 
structure stabilized the protein structure by connecting the two functional complex 
(TMD1-NBD1 and TMD2-NBD2) as a “spring” in order to maintain the protein structure 
and transmit domain motions. Similarly, in other ABC transporter structures such as 
ABCB1, the linker structure also lacks accurate crystal structure (102). The linker 
structure of ABCB1 was found by a homology modeling and MD simulation study to 
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stabilize the transporter in membrane system (103). The MD results in Figure 5A that 
TMD2 and NBD1 having higher equilibrated RMSD could be explained by direct 
connection with linker 2. The fluctuation of linker 2 will be transmitted to domains that 
are directly linked more easily. And with the distance to linker 2 increases, its influence 
in structural stability will become attenuated. 
Being an ATP-dependent efflux pump, analysis of the potential motion pattern of 
MRP7 will boost the understanding of the transportation mechanism. The PCA analysis 
revealed the potential motions of MRP7 at substrate-binding or ATP-binding states. 
Several studies on other ABC transporters have described essential mechanism of action 
related to the NBD dimerization after substrates and ATP-binding (67,102,104). For 
MRP1, the cryo-EM structures of inward- and outward-facing indicate that the ATP-
binding induces NBD closure which consequently triggers helices rotation and side chain 
movement as well as decreased substrate affinity (67).  
Subsequently, we performed binding site search as well as docking analysis to 
characterize the binding pockets of MRP7, where the major drug binding pocket buried in 
TMDs was focused. The binding pockets of MRP1 and MRP7 were also compared and 
analyzed. Unlike ABCB1, where the binding sites are characterized by a large number of 
aromatic (M site) and polar (R/H site) residues (105), and ABCG2, where the binding 
sites are majorly composed of hydrophobic residues (53), both MRP7 and MRP1 showed 
bipartite binding pockets with the existence of both polar and non-polar region. Although 
sharing the similar components, MRP7 and MRP1 still have different substrate/inhibitor 
spectrum, for example, multiple studies have shown that MRP1 is not able to mediate the 
transportation of paclitaxel (106,107) which is a substrate of MRP7 (108). Or the case of 
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methotrexate, which is a substrate of MRP1 but not MRP7. Such difference could be 
explained by the characteristics of the pockets such as volume and hydrophobicity. We 
found that paclitaxel had lower binding affinity to MRP1 is possibly due to the size of the 
pocket and distribution of polar residues. As a result, paclitaxel could only find the best 
docking site on the edge of the pocket, which has polar residues and larger volume. It is 
worth noting that although the different physiochemical properties of amino acids which 
form the binding pocket of MRP7 and MRP1 are one of the key factors that determined 
the transport pattern of paclitaxel, paclitaxel sensitivity is also determined by other 
intracellular macro-factors as well as metabolism pathways.   
Investigations of the transport properties of MRP7 revealed its ability to efflux 
conjugates such as E217bG and LTC4, indicating the existence of bipartite substrate 
binding pocket for anionic and hydrophobic moieties. In this study, we identified 4 
potential binding clefts with different hydrophobicity in MRP7 binding pockets, which 
were separated by a leucine in the center. The docking analysis of several previously 
validated MRP7 substrates provided more details of the binding pocket. More docking 
analysis was performed using more MRP7 substrates and modulators, from which we 
further confirmed the existence of binding clefts. Additionally, we found that MRP7 
modulators tend to occupy the hydrophobic cleft while substrates tend to occupy the 
polar cleft. Among the modulators we analyzed, cepharanthine, an herbal extract from 
Stephania cepharantha, unlike other modulators, binds at the polar site. This could be 
explained by the similarity in the chemical structures of cepharanthine as Vinca alkaloid, 
such as vincristine, which also binds to the polar site.  
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In summary, we performed a series of structure-function analysis using MD 
simulations and docking on homology models built from MRP1 crystal structures. Our 
findings provide new and valuable information for better understanding the structural 
dynamics and transport mechanism of human MRP7, as well as the potential drug-
binding sites within the TMDs of MRP7. Our model was also validated by docking 
analysis using known MRP7 substrates and inhibitors, as well as non-modulators. This 
MRP7 model could be a good starting point for future MRP7 studies regarding amino 
acid mutations in cancer patients to evaluate potential alterations of substrates/inhibitors 
binding pattern and pharmacokinetics. Moreover, our model would theoretically enable 




 The homology model of human MRP7 protein is critical in developing and 
understanding MRP7-mediated MDR in cancer cells. In this chapter, we majorly focused 
on the discovery of two synthesized compounds as potent MRP7 modulators where the 
homology model of human MRP7 was used in the docking simulations. 
2.1 Introduction 
Previously, a series of 1,2,3-triazole-pyrimidine hybrids and were synthesized. 
Among them, the compound CMP25 showed potent reversal activity against P-
glycoprotein (P-gp/ABCB1)-mediated MDR, which is 7-fold more potent than verapamil 
(109). Additionally, in a previously synthesized series of 5-cyano-6-phenylpyrimidin 
derivatives,  a compound named CP55 showed potent reversal activity against ABCB1-
mediated MDR in vitro and in mouse xenograft models (110). However, their interactions 
with MRP7 was not tested. In this chapter, we investigated the characteristics of CMP25 
and CP55 to reverse MRP7-mediated MDR. We found that both CMP25 and CP55 could 
significantly increase the cellular sensitivity to MRP7 substrates in MRP7-overexpressing 
cells by increasing the intracellular accumulation of MRP7-substrate chemotherapeutic 
drugs in vitro. 
2.2 Materials and methods 
Materials 
The 5-cyano-6-phenylpyrimidin derivative CP55 and 1,2,3-triazole-pyrimidine 
hybrids CMP25 were synthesized as previously described (110). Cell culture: Dulbecco's 
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modified Eagle's Medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin 
and trypsin were purchased from Hyclone (Pittsburgh, PA). 
Cell lines and cell culture 
In this study we used HEK293/pcDNA3.1 and MRP7-transfected HEK293/MRP7 
cells. HEK293pcDNA3.1 and HEK293/MRP7 was established by transfecting empty 
vector pcDNA3.1 or MRP7-expressing recombinant vector as previously described (100). 
Cells were maintained and cultured in DMEM with 10% FBS, 100 units/mL 
penicillin/streptomycin and 2 mg/mL G418. At least one week prior to experiment, we 
transfer cells to DMEM without G418. 
Cytotoxicity assay 
Cytotoxicity of CMP25 and CP55 in HEK293/pcDNA3.1 and HEK293/MRP7 
cells was evaluated using MTT colorimetric assay as previously described (111). To be 
brief, the HEK293/pcDNA3.1 and HEK293/MRP7 cells were seeded in 96-well plates at 
5,000-7,000 cells per well. Cells were cultured overnight before addition of 0 – 100 𝜇M 
CMP25 and CP55 for toxicity assay. Different concentrations of MRP7 modulators 
cepharanthine or CMP25 and CP55 were preincubated with cells for 2 h before different 
concentrations of paclitaxel/vincristine/vinblastine/cisplatin were added, after which 
plates were cultured for 68 h. Then MTT was added to each well to a final concentration 
of 0.4 mg/ml and incubated for additional 4 h (72 h in total). Then medium was removed, 
and the formazan crystal was dissolved in DMSO. Absorbance at 570 nm was determined 
by a spectrophotometer. IC50 was calculated using modified Bliss method (112). 
Resistance fold (RF) was the ratio of IC50 in HEK293/MRP7 and HEK293/pcDNA3.1 
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cells. Cepharanthine was used as a positive reversal agent of MRP7. Cisplatin, a non-
substrate of MRP7, was used as a negative control drug.  
Western blotting 
Western blotting was performed as previously described with modifications (113). 
Briefly, HEK293/pcDNA3.1 and HEK293/MRP7 cells were seeded in T-25 flasks with 
equal amount. For concentration-dependent study, CMP25 or CP55 was added to cells in 
different concentrations (1 or 3 𝜇M) and incubated for 72 h. For time-dependent study, 
cells were incubated with the same concentration (3 𝜇M) of CMP25 or CP55 for 
0/24/48/72 h. On the day of cell lysis, cells were first rinsed with ice-cold PBS twice 
before adding lysis buffer. Cells were scraped down from flasks and lysates were 
incubated for 30 min on ice. Then cell lysate was centrifuged at 12,000 rpm at 4 °C for 
20 min. Supernatant was collected for further analysis. Protein concentration was 
determined by bicinchoninic-acid-based protein assay (BCA). Subsequently, equal 
amount of total protein (20-30 𝜇g) was separated by SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) and transferred onto PVDF (polyvinylidene 
difluoride) membranes. The membranes were incubated in blocking solution (5% skim 
milk in TBST) at room temperature for 2 h, followed by incubation with anti-MRP7 
(1:1000) and anti-GAPDH (1:1000) primary antibody at 4 °C overnight. Afterwards, 
membranes were rinsed with TBST and incubated with HRP-conjugated secondary 
antibody (1:1000) at room temperature for 2 h. MRP7 and GAPDH protein was detected 
using enhanced photodope TM-HRP detection kit (Cell Signaling Technology) and 




Immunofluorescence was performed following the protocol described previously 
with slight modifications (114). Cells (1 × 105 per well) were seeded into 6-well plates. In 
order to prevent cells from detaching, poly-lysine-processed cover slips were set at the 
bottom of each well. For time-dependent study, cells were treated for 0/24/48/72 hours 
with 3 𝜇M CMP25 or CP55; for concentration-dependent study, cells were treated 72 
hours with 1 or 3 𝜇M CMP25 or CP55. Next, cells were fixed with 4% formaldehyde in 
37 °C for 15 min. Then 0.1% Triton X-100 was added for permeabilization and then 6% 
BSA for blocking for 2 h in 37 °C. Subsequently, cells were incubated with MRP7 
monoclonal antibody (1:1000) at 4 °C overnight followed by incubation with Alexa Fluor 
594 conjugated secondary antibody (1:1000) for 1 h at 37 °C. PI (propidium iodide) was 
used to dye the nuclei. Before imaging, cover slips were transferred to a microslide and 
mounted with glycerol. Images were taken using a fluorescence microscope. 
 [3H]-labeled MRP7 substrate accumulation assay 
[3H]-paclitaxel and [3H]-vincristine accumulation were determined as previously 
described with slight modifications (115).  
 [3H]-labeled MRP7 substrate efflux assay 
Efflux assay was performed as previously described with slight modification 
(116).  
Docking analysis 
The CMP25 or CP55 structure was prepared for docking simulation as previously 
described (77). Human MRP7 homology model bound with paclitaxel was established in 
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our lab (117). The protein model was inward-facing. Docking calculations were 
performed in AutoDock Vina (v 1.1.2) (118).  
2.3 Results 
Cytotoxicity of CMP25/CP55 in HEK293/pcDNA3.1 and HEK293/MRP7 
cells 
Cytotoxicity assay was performed for two goals: a) compare the cytotoxicity 
(IC50) of CMP25 or CP55 in parental and MRP7-mediated resistant cells to determine 
whether CMP25 or CP55 is a potential MRP7 substrate; b) determine the non-toxic 
concentration (at least 80% cells survive) of CMP25 or CP55 for reversal study. The 
results of cytotoxicity assay were presented in Figure 11 (CMP25) and 12 (CP55). 
Results showed that there is no significant difference in the IC50’s of CMP25 or CP55 in 
parental and MRP7-transfected cells. Therefore, we chose two non-toxic concentrations 
(1 and 3 𝜇M) for reversal study. 
 
Figure 11. Chemical structure and cytotoxicity of CMP25. A) 2D chemical structure of 
CMP25. B) Cytotoxicity of CMP25 in HEK293/pcDNA3.1 and MRP7. 80% and 50% 




Figure 12. Chemical structure and cytotoxicity of CP55. A) 2D chemical structure of 
CP55. B) Cytotoxicity of CP55 in HEK293/pcDNA3.1 and HEK293/MRP7 cells. 
 
 
Reversal effects of CMP25/CP55 in HEK293/MRP7 cells 
Results of reversal study were shown in Figure 13 (CMP25) and 14 (CP55). In the 
reversal study, we used 1 and 3 𝜇M of CMP25/CP55. The results showed that in both 
concentrations co-treatment with CMP25/CP55 significantly decreased the IC50 of 
MRP7-substrate antineoplastic drugs, while 3 𝜇M of CMP25/CP55 showed stronger 
reversal effects than lower concentration. Results in Figure 13 and 14 showed that the 
HEK293/MRP7 concentration-viability curves of paclitaxel, vincristine and vinblastine 
shifted left when co-administered with CMP25/CP55 or cepharanthine compared with 
control group. For parental HEK293/pcDNA3.1 cell, no significant change was observed 
with CMP25/CP55 or cepharanthine. For cisplatin, which is not a substrate of MRP7, 
both MRP7-transfected and parental cells showed similar concentration-viability curves 




Figure 13. Reversal effects of CMP25 in MRP7-overexpressing cells. Concentration-
viability curves of A) paclitaxel; B) vincristine; C) vinblastine; D) cisplatin. Results of 
parental cells HEK293/pcDNA3.1 were displayed as dash lines; HEK293/MRP7 were 
displayed as solid lines. Results were expressed as mean ± SD, representative of three 
independent experiments in triplicate. 
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Figure 14. Reversal effects of CP55 in ABCC10-overexpressing cells. Concentration-
viability curves of A-B) paclitaxel; C-D) vincristine; E-F) vinblastine; G-H) cisplatin. 
Results of parental cells HEK293/pcDNA3.1 were displayed in A, C, E and G; 
HEK293/ABCC10 were displayed in B, D, F and H. Data are expressed as mean ± SD, 
representative of three independent experiments in triplicate. 
 


















To verify whether the reversal effects was due to regulated MRP7 protein 
expression in HEK293/MRP7 cells, we treated both parental and resistant cells with 
CMP25/CP55 and determined the protein expression level via Western blot. First, we 
verified the expression of MRP7 in transfected cells. Specifically, cells were treated with 
a) 1 or 3 µM CMP25/CP55 for 72 h or b) 3 µM CMP25/CP55 for 0, 24, 48 or 72 h. 
Figure 15 and 16 confirmed the expression of MRP7 protein in transfected 
HEK293/MRP7 cells and no MRP7 was detected in parental HEK293/pcDNA3.1 cell. 
Figure 15 and 16 showed that treatment with CMP25/CP55 did not significantly alter the 
protein expression level of MRP7. Thus, we drew the conclusion that the reversal effects 
on MRP7 was not due to regulating the expression level of MRP7 protein. 
 
Figure 15. Effect of CMP25 on the MRP7 protein expression. (A) MRP7 expression in 
HEK293/pcDNA3.1 and HEK293/MRP7 cells. GAPDH was used as a loading control. 
(B) HEK293/MRP7 cells treated with 1 or 3 µM CMP25 for 72 h. (C) HEK293/MRP7 
cells treated with 3 µM CMP25 for 0/24/48/72 h. Columns with error bars represent mean 
± SD from 3 independent triplicate experiments. Asterisks (*) indicate p < 0.05 versus 
parental group (HEK293/pcDNA3.1). 
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Figure 16. Effect of CP55 on the MRP7 protein expression. (A) MRP7 expression in 
HEK293/pcDNA3.1 and HEK293/MRP7 cells. GAPDH was used as a loading control. 
(B) Protein expression quantification. Columns with error bars represent mean ± SD from 
3 independent triplicate experiments. Asteroid (*) indicate p < 0.05 versus parental group 
(HEK293/pcDNA3.1). 
 
 The effect of CMP25/CP55 on the intracellular accumulation of MRP7-
substrate anticancer drugs 
The above results demonstrated the reversal effect of CMP25/CP55 in 




obtain more insight into the mechanism of action, intracellular MRP7 substrate 
accumulation was measured in parental and MRP7-overexpressing cell lines. As shown 
in Figure 17 and 18, CMP25/CP55 significantly increased the intracellular accumulation 
of [3H]-paclitaxel in HEK293/MRP7 cells, without significant changes in parental 
HEK293/pcDNA3.1 cell. The intracellular accumulation in HEK293/MRP7 cells treated 
by CMP25/CP55 is comparable to that treated with positive modulator cepharanthine. 
Similar results were also observed in the accumulation of [3H]-vincristine. Resistant cells 
treated with CMP25/CP55 showed higher intracellular accumulation level when 
comparing to control group without modulators. 
 
Figure 17. Effect of CMP25 on the intracellular accumulation of [3H]-paclitaxel and 
[3H]-vincristine in parental and MRP7-transfected cells. (A) Effect of CMP25 on [3H]-
paclitaxel accumulation in HEK293/pcDNA3.1 and HEK293/MRP7 cells. (B) Effect of 
CMP25 on [3H]-vincristine accumulation in HEK293/pcDNA3.1 and HEK293/MRP7 
cells. Columns with error bars represent mean ± SD from three independent duplicate 





Figure 18. Effect of CP55 on the intracellular accumulation of [3H]-paclitaxel and [3H]-
vincristine in parental and MRP7-transfected cells. (A) Effect of CP55 on [3H]-paclitaxel 
accumulation in HEK293/pcDNA3.1 and HEK293/ MRP7 cells. (A) Effect of CP55 on 
[3H]-vincristine accumulation in HEK293/pcDNA3.1 and HEK293/ MRP7 cells. 
Columns with error bars represent mean ± SD from three independent duplicate 
experiments. Asteroids (*) indicate p < 0.05 versus control group (untreated resistant 
cells). 
 
The effect of CMP25/CP55 on efflux of MRP7-substrate anticancer drugs 
To further confirm whether the elevated intracellular accumulation of paclitaxel 




efflux of [3H]-paclitaxel or [3H]-vincristine in parental and resistant cells. In Figure 19 
and 20, the remaining intracellular amount of [3H]-paclitaxel or [3H]-vincristine in 
MRP7-overexpresing cells was significantly lower than that of HEK293/pcDNA3.1 and 
in the absence of CMP25/CP55. Treatment with 3 µM CMP25/CP55 significantly 
decreased the efflux of [3H]-paclitaxel or [3H]-vincristine in MRP7-overexpressing cells. 
Furthermore, the results in HEK293/MRP7 were comparable to that of the positive 
control inhibitor cepharanthine. 
 
Figure 19. Effects of CMP25 on the efflux of [3H]-paclitaxel and [3H]-vincristine in 
parental and MRP7-transfected cells. X-axis represents time course (0/30/60/120 min). 
Y-axis represents the percentage of remaining intracellular of [3H]-paclitaxel or [3H]-
vincristine. (A) [3H]-paclitaxel efflux in HEK293/pcDNA3.1, (B) [3H]-paclitaxel efflux 
in HEK293/MRP7, (C) [3H]-vincristine efflux in HEK293/pcDNA3.1, (D) [3H]-
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vincristine efflux in HEK293/MRP7. Points with error bars represent mean ± SD from 3 
independent duplicate experiments. Asterisks (*) indicate p < 0.05 versus control group 
(untreated resistant cells). 
 
 
Figure 20. Effects of CP55 on the efflux of [3H]-paclitaxel and [3H]-vincristine in 
parental and MRP7-transfected cells. Time course versus the percentage of remaining 
intracellular of [3H]-paclitaxel or [3H]-vincristine was plotted to illustrate the effect of 
CP55 on [3H]-paclitaxel efflux in (A) HEK293/pcDNA3.1, (B) HEK293/MRP7or [3H]-
paclitaxel efflux in (C) HEK293/pcDNA3.1, (D) HEK293/MRP7. Points with error bars 
represent mean ± SD from 3 independent duplicate experiments. Asterisks (*) indicate p 
< 0.05 versus control group (untreated resistant cells). 
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The effect of CMP25/CP55 on the subcellular localization of MRP7 
Another potential mechanism of the antagonization of CMP25/CP55 on MRP7 is 
the alteration of sub-cellular localization. Thus, we performed immunofluorescence assay 
to determine whether CMP25/CP55 could alter the subcellular localization of MRP7 
transporters. As shown in Figures 21 and 22, MRP7 located on the membrane of 
HEK293/MRP7 cells. After incubating for 24, 48, and 72 h, CMP25/CP55 did not 
significantly alter the localization of MRP7. Incubating with different concentrations of 
CMP25/CP55 also did not alter the localization of MRP7. Above results indicate 
CMP25/CP55 did not affect the subcellular localization of MRP7. 
 
Figure 21. The effect of CMP25 on subcellular localization of MRP7 transporters. Left 
two columns: the expression and localization of MRP7 expression in HEK293/MRP7 
cells (0 h). 3rd and 4th columns: sub-cellular localization of MRP7 expression in 
HEK293/MRP7 cells incubated with 1 or 3 µM of CMP25 for 72 h. 5th, 6th and 7th 
columns: Sub-cellular localization of MRP7 expression in HEK293/MRP7 cells 
incubated with 3 µM of CMP25 for 24, 48, and 72 h. Red: MRP7. Blue: DAPI 




Figure 22. The effect of CP55 on subcellular localization of MRP7 transporters. Sub-
cellular localization of MRP7 expression in HEK293/MRP7 cells incubated with 0.5, 1 or 
3 µM of CP55 for 72 h; or 3 µM of CP55 for 0, 24, 48, and 72 h. Red: ABCC10. Blue: 
DAPI counterstains the nuclei. Scale bar: 50 µm. 
 
Molecular docking and molecular dynamics simulation 
To better understand the potential interaction between CMP25/CP55 and MRP7 
protein, we performed molecular docking simulation and molecular dynamics simulation. 
Compound CMP25 has a high docking score of -8.974 kcal/mol in the predicted substrate 
binding pocket of MRP7. The docked complex showed that CMP25 was stabilized by 
both polar and hydrophobic interactions. The compound CMP25 was stabilized by a 
hydrogen bond, as well as a π-cation interaction with Arg985. Additionally, CMP25 was 
stabilized in the hydrophobic pocket formed by Ala542, Met546, Ile548, Leu549, 
Ile1045, Ala1048 and Asn1049. Docked complex with highest docking score was 
subjected to a 10 ns molecular dynamics simulation. The results in Figure 23 showed that 
the structures of both protein and ligand reached equilibrium after the first 5 ns. CMP25 
 55 
had an overall displacement of 4 Å and MRP7 (protein) was stable with a root mean 
square deviation (RMSD) of around 6 Å, indicating only small internal fluctuation inside 
the drug-binding site of the protein. Compound CP55 has a high docking score of -9.023 
kcal/mol in the predicted binding pocket of MRP7. The docked complex showed that 
CP55 was stabilized by both polar and hydrophobic interactions (Figure 24). The 
compound CP55 was stabilized by hydrogen bonds formed with residue Asn1049 and 
Leu1192, as well as a salt bridge interaction with Arg545. Additionally, CP55 was 
stabilized in the hydrophobic pocket formed by Trp510, Ala511, Pro514, Val515, 
Leu549, Met546, Leu1192, Ser1193, Thr1195, Gly1196, Leu1197 and Gly1200. 
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Figure 23. Interaction between CMP25 and MRP7 protein by docking simulation and 
molecular dynamics. A) An overview of the docked complex. Compound CMP25 
molecule was displayed as balls marked by black square. B) Interaction between CMP25 
and MRP7 protein. Top: MRP7 binding pocket was displayed as grey meshes. Down: 
Docked position of CMP25 within the binding pocket of MRP7. CMP25 was showed as 
colored sticks. Carbon: orange, nitrogen: blue, white: polar hydrogen, green: chloride, 
yellow: sulfur. C) Root mean square deviation (RMSD) of MRP7 (blue) and CMP25 
(red) versus reference time (ns). D) 2D interaction diagram of CMP25-MRP7. The amino 
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acids within 3 Å are shown as colored bubbles, cyan indicates polar residues, and green 
indicates hydrophobic residues. The purple arrow indicates hydrogen bond and red line 
shows π-cation interaction. 
 
 
Figure 24. Interaction between CP55 and MRP7 protein by docking analysis. A) An 
overview of the docked complex. Compound CP55 molecule was displayed as balls 
marked by black square. B) Interaction between CP55 and MRP7 protein. MRP7 binding 
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pocket was displayed as grey meshes. C) Docked position of CP55 within the binding 
pocket of MRP7. CP55 was showed as colored sticks. Carbon: green, nitrogen: blue, 
white: polar hydrogen, dark green: chloride, yellow: sulfur, red: oxygen. D) 2D 
interaction diagram of CP55-MRP7. The amino acids within 3 Å are shown as colored 
bubbles, cyan indicates polar residues, and green indicates hydrophobic residues. The 
purple arrows indicate hydrogen bonds. 
 
2.4 Discussion 
Till now only a few studies reported MRP7 modulators since it’s relatively new. 
Considering the important biological role that MRP7 plays in cancers, it is of great value 
to develop novel MRP7 inhibitors for both research and clinical purpose. Previously, we 
reported for the first time that CMP25 and CP55 potently reverse ABCB1-mediated 
MDR by inhibiting the efflux function of ABCB1 hence increasing the intracellular 
accumulation of chemotherapeutic agents such as paclitaxel in vitro. However, the effects 
of CMP25/CP55 on MRP7 was not determined yet. Here, we examined the potential 
inhibitory effects of CP55 and CMP25 on MRP7 by using HEK293/pcDNA3.1 and 
HEK293/ MRP7 cells.  
Generally speaking, modulators of ABC transporters were composed of 
substrates, which are delivered by ABC transporters across membranes and usually 
stimulate the ATPase activity locates in the nucleotide binding domains, and inhibitors, 
which inhibits the transportation of substrates with different mechanisms (6). We first 
examined whether CMP25 or CP55 is a substrate of MRP7. The cytotoxicity assay 
showed that there is no significant difference in the IC50 values of parental and MRP7-
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overexpressing cells for both drugs. Since MRP7 substrates will have higher IC50 due to 
the detoxification (efflux) function of MRP7, our results indicated that CMP25 or CP55 
is not an MRP7 substrate. Meanwhile, we obtained the non-toxic concentration of CP55 
and performed reversal study via MTT assay. Our results showed that CP55 at 1 or 3 µM 
significantly reversed the resistance of paclitaxel, vincristine and vinblastine in 
HEK293/MRP7 cells while not affecting their cytotoxicity in parental cells 
HEK293/pcDNA3.1. Also, there was no significant effect on the IC50 of cisplatin, which 
is not an MRP7 substrate. Altogether, our results indicate that CP55 antagonizes the 
MDR mediated by MRP7.  
Altered MRP7 protein level could be one of the underlying mechanisms of 
reversed MRP7-mediated MDR. For example, the ABC transporter inhibitor poziotinib 
down-regulated the expression level of ABCG2 and conferred reversal effects on 
ABCG2-mediated MDR (116). The Western blotting results measured the protein 
expression level after treating cells with CMP25 and CP55. Our results confirmed that the 
MRP7 expression level was not significantly altered after treatment CMP25 or CP55. 
Thus, the reversal effect of CP55 on MRP7-mediated MDR was not due to alteration in 
MRP7 expression.  
Functional MRP7 locates majorly on the cytoplasm membrane (119). As a 
membrane protein, altered subcellular localization of MRP7 could also lead to 
deteriorated transport function. Here, we determined the subcellular localization using 
immunofluorescence assay. The results showed that HEK293/MRP7 cells treated with 
CMP25 or CP55 did not show altered localization of MRP7.  
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The [3H]-paclitaxel and [3H]-vincristine accumulation assay showed that CP55 
significantly enhanced the intracellular accumulation of paclitaxel and vincristine in 
HEK293/MRP7 cells. Subsequently, a time course of efflux study was performed to 
further confirm the accumulation results. Our results showed that the efflux of 
intracellular paclitaxel or vincristine was significantly inhibited by CMP25 or CP55 in 
the HEK293/MRP7 cells, while resistant cells without adding CMP25 or CP55 showed 
significantly lower intracellular accumulation. Besides, the blockage of efflux by CMP25 
or CP55 is comparable to the known MRP7 inhibitor cepharanthine. Hence, the above 
results along with cytotoxicity data indicate that both CMP25 and CP55 are potent MRP7 
inhibitors which block the efflux function of MRP7 protein. 
Furthermore, we performed docking analysis using an MRP7 homology model 
(117). The docking score of both compounds in MRP7 binding pocket are high. 
Moreover, both compounds potentially bind at the predicted “inhibitor site” formed by 
amino acids Trp510, Ala511, Val515, Arg545, Leu549, Arg985, Ala1048 and Asn1049. 
Based on our study, molecules bound in the inhibitor site exhibit properties as MRP7 
inhibitors such as efficiently reversing MRP7-mediated MDR. 
Clinically, MRP7 has been reported to play important roles in acquired MDR and 
the prognosis of certain cancers (51,120). Also, MRP7 contributes to alteration in 
intracellular permeation of nevirapine, a non-nucleoside reverse transcriptase inhibitor for 
HIV-1 (121). Thus, development of MRP7 inhibitors is crucial in cancer treatment to 
overcome MRP7-mediated drug resistance. Here we reported two novel synthetic small 
molecules CMP25 and CP55 as potent MRP7 inhibitors, which could be potential 
adjuvant chemotherapeutic agents. 
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CHAPTER 3 
 In this chapter, we describe the establishment of an MRP7-overexpression ovarian 
cancer cell line.  
3.1 Introduction 
Here, we successfully established an MRP7-overexpressing SKOV3/MRP7 cell 
line by transfecting recombinant pcDNA3.1/MRP7 plasmids. The MRP7 expression and 
subcellular localization was confirmed by Western blotting and immunofluorescence 
assay respectively, indicating functional MRP7 transporter was produced. Moreover, the 
SKOV3/MRP7 cell line showed MDR to multiple chemotherapeutic drugs including 
paclitaxel, docetaxel, vincristine, vinorelbine, vinblastine but not to doxorubicin and 
cisplatin. Additionally, the MDR in SKOV3/MRP7 cells could be reversed by a known 
MRP7 inhibitor cepharanthine. In conclusion, overexpression of MRP7 in ovarian cancer 
could be an important factor in acquiring drug resistance to several commonly used 
chemotherapeutic drugs. 
3.2 Materials and methods 
Chemicals and reagents 
Chemotherapeutic drugs and reagents used in this study were purchased from 
Sigma Chemical Co if otherwise stated (St. Louis, MO) including paclitaxel, docetaxel, 
vincristine, vinorelbine, vinblastine, doxorubicin, formaldehyde, Triton X-100, 3-(4, 5-
dimethylthiazol-yl)-2, 5-diphenyltetrazolium bromide (MTT). Cisplatin, geneticin (G418) 
were purchased from Enzo Life Sciences (Farmingdale, NY). Recombinant MRP7 
plasmid was prepared as previously described (122). Anti-MRP7 antibody (HPA041607) 
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produced in rabbit was purchased from Sigma-Aldrich, Inc. (St. Louis, MO). The [3H]-
paclitaxel was purchased from Moravek Biochemicals, Inc (Brea, CA). Fetal bovine 
serum (FBS), Dulbecco’s modified Eagle’s medium (DMEM), and 0.25% trypsin-EDTA 
were ordered from Corning Inc. (New York, NY). Phosphate buffer saline (PBS), 
dimethyl sulphoxide (DMSO), the Alexa Fluor 488-labeled secondary antibody (anti-
mouse), 4,6-diamidino-2-phenylindole (DAPI) were ordered from Thermo Fisher 
Scientific Inc. (Rockford, IL). 
Cell lines and cell culture 
The human ovary adenocarcinoma cell line SKOV3 was purchased from ATCC 
(Manassas, VA). The HEK293 and HEK293/MRP7 cell lines were established and 
maintained as previously described (119). Both transfected cell lines were selected and 
cultured in DMEM with 10% FBS and 2 mg/mL G418 in a 5% CO2 incubator at 37°C.  
Recombinant MRP7 plasmid transfection 
The recombinant expression vector of MRP7 was established based on pcDNA3.1 
plasmid as previously described (122). Transfection of the empty or recombinant vector 
into SKOV3 was performed using Fugene6 transfection agent (Promega, Madison, WI) 
following the manufacturer’s instructions. In brief, SKOV3 cells were seeded in 6-well 
plates with 100,000 to 200,000 cells per well with DMEM with 10% FBS. Then 100ml 
mixture of plasmid DNA and Fugene6 reagent (1:3 DNA:Fugene6 ratio) was prepared 
and incubated at room temperature for 30 min. Then the mixture was added into cell 
culture medium and incubated with cells for 2 days. When incubation ends, cell culture 
medium with transfection reagent was removed and transfected cells were rinsed with 
PBS. Selection medium (DMEM, 10% FBS and 2 mg/ml G418) was added and incubated 
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with cells for at least 14 days. Survived cells that formed single colonies were collected 
and cultured separately. The expression of MRP7 was further verified by Western 
blotting and immunofluorescence assay. In this paper, we use “SKOV3” to represent 
empty-vector-transfected “SKOV3/pcDNA3.1” unless otherwise stated. 
Cell viability assay 
The cell viability was measured by modified MTT assay as previously described 
with slight modifications (111). In brief, cells were seeded at a density of 6,000-8,000 
cells/well in 96-well plates 24 h prior to adding drugs. Then cells were treated with 
different concentration of chemotherapeutic drugs for 72 h. For reversal study, MRP7 
inhibitor cepharanthine were added to the 96-well plates 2 h before adding 
chemotherapeutic drugs. At the end of the treatment, cell viability was determined by 
MTT assay. Resistance fold was determined as fold relative to parental control groups. 
The half maximal inhibitory concentrations (IC50) were calculated using the regression 
algorithm provided in GraphPad Prism 8. 
Western blotting 
Western blotting was performed as previously described with slight modifications 
(114). The previously established HEK293/MRP7 cell line was used as a positive control 
of MRP7. The whole protein in cell lysate was separated using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and electro-transferred to a polyvinylidene difluoride 
(PVDF) membrane. Then the membrane was blocked by 5% non-fat milk for 2 h at room 
temperature. The primary antibodies (1:1000 dilution) of MRP7 (HPA041607) and 
GAPDH were incubated with the blocked membrane at 4°C overnight. After rinsed with 
TBST for 3 times (15 min each), the membrane was incubated in the secondary HRP-
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linked antibody (1:1,000 dilution) for 2 h at room temperature. Blotted protein bands 
were visualized using an enhanced ECL kit (Thermo Fisher Scientific Inc., Waltham, 
MA). 
Immunofluorescence assay 
In brief, SKOV3 and SKOV3/MRP7 cells were seeded in 24-well plates at a 
density of 50,000 cells/well and cultured overnight. Immunofluorescence assay was 
performed as previously described with slight modifications (99). In brief, cells were 
processed with 4% formaldehyde (37°C for 15 min) and 0.1% Triton X-100 (37°C for 15 
min). Cells were rinsed with cold PBS between each step. Next, cells were incubated 
with primary anti-MRP7 (1:200) at 4°C overnight followed by incubation with Alexa 
Fluor 488 conjugated secondary antibody (1:1,000) for 2 h at 37 °C. DAPI was used to 
visualize the nuclei. Images were taken using a fluorescence microscope. 
Accumulation and efflux assay  
Accumulation and efflux assay were performed as previously described with 
slight modifications (123). In brief, Cell were seeded 10,000 cells/well into 24-well plates 
and cultured overnight. Then cells were incubated in culture medium containing 10 nM 
[3H]-paclitaxel at 37°C for 2 h. After incubation, cells were rinsed with cold PBS and 
incubated in [3H]-free medium for 0, 0.5, 1 and 2 h. At each time point, cells were 
detached and transferred into 5 ml scintillation fluid. The radioactivity was measured 
using a Tri-Carb liquid scintillation counter (Packard Instrument Inc., Chicago, IL). The 
[3H]-paclitaxel level at 0 h was used to represent the intracellular accumulation within 2 h 
incubation. The change in [3H]-paclitaxel levels at following time points were used to 
measure the efflux activity. 
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Statistical analysis 
Comparison of differences among groups were performed using one-way 
ANOVA. The statistical criteria p < 0.05 was considered as statistically significant. All 
data were represented as mean ± SD from at least three independent experiments. 
3.3 Results 
Verification of the MRP7 expression and paclitaxel resistance in G418-
selected SKOV3/MRP7 colonies 
After culturing with selection medium containing 2 mg/ml G418 for 14 days, 
three colonies were collected and cultured for 1 week. Western blotting was performed 
when cells were 80% confluent. Results were shown in Figure 1. From the results in 
Figure 25, we can see that colony 1 exhibited the highest MRP7 expression. Moreover, it 
is worth noting that endogenous MRP7 expression was also detected in parental SKOV3 
cells, even though the expression level was low. Furthermore, we examined the 
cytotoxicity of paclitaxel, a known substrate of MRP7, to see if the selected cell lines 
become resistant. Based on the results in Figure 25, only colony 1 showed significantly 
increased paclitaxel IC50, indicating the acquired resistance from MRP7 overexpression. 
To further analyze the resistance profile of the new SKOV3/MRP7 cell line, we chose 
colony 1 for following steps. 
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Figure 25. MRP7 expression and paclitaxel cytotoxicity in SKOV3/MRP7 cells. 
HEK293/MRP7 and SKOV3 were used as positive and negative controls, respectively. 
A) Western blotting results showing MRP7 expression of selected colonies and 
positive/negative controls. B) Cytotoxicity of paclitaxel in selected colonies and 
positive/negative controls. C) Qualitative analysis of MRP7 protein expression showed in 
A). D) Paclitaxel IC50 in selected colonies and positive/negative controls. * p < 0.05 
versus the negative control group. 
Subcellular localization of MRP7 
Similar to other ABC transporters, MRP7 requires membrane localization for 
efflux function. Therefore, we examined the subcellular localization of SKOV3/MRP7 
cells via immunofluorescence assay. In parental SKOV3 cells, no detectable green 
fluorescence was observed under the same parameters, which was consistent with the low 
expression level of endogenous MRP7 in SKOV3 cells. Strong green fluorescence was 
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observed on the membrane of SKOV3/MRP7 cells, suggesting that the overexpressed 
MRP7 transporter is localized on the cell membrane. 
Intracellular accumulation of [3H]-paclitaxel in SKOV3 and SKOV3/MRP7 
We measured the intracellular accumulation of [3H]-paclitaxel in SKOV3 and 
SKOV3/MRP7 after incubation in [3H]-paclitaxel-containing culture medium for 2 h. The 
results in Figure 26 showed significant different levels of intracellular accumulation of 
paclitaxel in SKOV3 and SKOV3/MRP7 cells. Specifically, SKOV3/MRP7 showed 
lower intracellular accumulation of paclitaxel than SKOV3. Moreover, in SKOV3/MRP7, 
the reduced paclitaxel accumulation was significantly reversed by MRP7 inhibitor 
cepharanthine. Above findings are consistent with previous MTT results that 
SKOV3/MRP7 was less sensitive to paclitaxel due to the overexpression of MRP7 
protein. 
Efflux of [3H]-paclitaxel in SKOV3 and SKOV3/MRP7 
In the previous section, we found SKOV3/MRP7 cells showed lower paclitaxel 
intracellular accumulation, which could be significantly antagonized by MRP7 inhibitor 
cepharanthine. We then determined the efflux of paclitaxel by measuring the decreased 
intracellular amount at 0, 0.5, 1 and 2 h. Results in Figure 26 showed that by the end of 
the 2-hour incubation, the intracellular concentration of paclitaxel was decreased by 
approximately 15% in SKOV3 cells. While in SKOV3/MRP7, intracellular paclitaxel 
concentration was decreased by approximately 40%, indicating strong efflux of paclitaxel 
mediated by MRP7 transporter. The efflux function of MRP7 was inhibited by 




Figure 26. Immunofluorescence assay and accumulation-efflux assay. A) Subcellular 
localization of MRP7 transporter in SKOV3 and SKOV3/MRP7 cells. B) The 
intracellular accumulation of [3H]-paclitaxel in SKOV3 and SKOV3/MRP7 cells. C) The 
efflux of [3H]-paclitaxel in SKOV3 cells. D) The efflux of [3H]-paclitaxel in 
SKOV3/MRP7 cells. Data in B-D are expressed as mean ± SD derived from three 
independent experiments. *p < 0.05 versus the control groups. 
The drug resistance profile of MTP7-overexpressing ovarian cancer cell line 
In previous sections, we have confirmed the successful establishment of an 
MRP7-overexpressing SKOV3 cell line. MTT assay and accumulation-efflux assay have 
confirmed the expression and biological function of the MRP7 protein. To further 
understand the drug resistance profile of the MRP7-overexpression ovarian cancer cell 
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line, we performed MTT assay to test the sensitivity to commonly used chemotherapeutic 
drugs. Results were displayed in Table 4. Specifically, SKOV3/MRP7 showed significant 
resistance to paclitaxel (10.43-fold resistance), docetaxel (3.82-fold resistance), 
vincristine (5.09-fold resistance), vinorelbine (6.86-fold resistance) and vinblastine (5.34-
fold resistance). Moreover, SKOV3/MRP7 showed no significant resistance to P-
gp/BCRP substrate doxorubicin. Also, SKOV3/MRP7 was not resistant to non-ABC-
transporter-substrate cisplatin. Overall, the resistance profile of SKOV3/MRP7 was 
consistent with HEK293/MRP7 based on previous reports (90,119,124). 
 
Table 4. The cytotoxicity of chemotherapeutic drugs in SKOV3 and SKOV3/MRP7 cell 
lines 
Drugs 
IC50 value ± SD (nM)  
SKOV3  SKOV3/MRP7 Resistance fold a 
Paclitaxel 4.483 ± 0.163 46.76 ± 4.565 10.43* 
Docetaxel 3.645 ± 0.201 13.92 ± 1.715 3.82* 
Vincristine 3.355 ± 0.527 17.08 ± 2.033 5.09* 
Vinorelbine 5.272 ± 0.523 36.16 ± 5.558 6.86* 
Vinblastine 2.640 ± 0.463 14.12 ± 2.847 5.34* 
Doxorubicin 0.184 ± 0.012 (µM) 0.169 ± 0.012 (µM) 0.92 
Cisplatin 4.342 ± 1.014 (µM) 5.200 ± 0.918 (µM) 1.20 
a Resistance fold was calculated by dividing the IC50 values of the SKOV3/MRP7 cells 
by the IC50 of SKOV3 cells 
* p < 0.05 versus the control group 
 70 
MRP7 inhibitor cepharanthine antagonizes the drug resistance phenotype of 
SKOV3/MRP7 cells 
To further confirm that the overexpression of MRP7 is the major contributing 
factor of drug resistance, we performed MTT assay with co-treatment of 
chemotherapeutic drugs and MRP7 inhibitor cepharanthine. As shown in Figure 27, cell 
viability curves of SKOV3/MRP7 showed left-shifting when adding cepharanthine, 
indicating resistance to known MRP7-substrate drugs were reversed in SKOV3/MRP7 by 
cepharanthine. Specifically, significant changes were observed in the IC50 of paclitaxel 
(from 33.76 nM to 7.61 nM), docetaxel (18.92 nM to 7.00 nM), vincristine (17.01 nM to 
6.10 nM), vinblastine (14.12 nM to 4.23 nM) and vinorelbine (30.24 nM to 10.39 nM). 
The cell viability of parental SKOV3 cells were not significantly affected by 
cepharanthine. Cisplatin was used as a negative control since it is not a substrate of major 




Figure 27. Reversal of MRP7-mediated drug resistance using cepharanthine in SKOV3 
and SKOV3/MRP7 cells. Chemotherapeutic drug versus cell viability was plotted. A) 
paclitaxel; B) vinorelbine; C) docetaxel; D) vinblastine; E) vincristine; F) cisplatin. Green 
solid lines represent SKOV3, green dashed lines represent SKOV3 + 3 µM 
cepharanthine, red solid lines represent SKOV3/MRP7, red dashed lines represent 
SKOV3/MRP7 + 3 µM cepharanthine. CEP: cepharanthine. Data are expressed as 
mean ± SD derived from three independent experiments. 
3.4 Discussion 
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Overall, our results suggest that overexpression of MRP7 could be a critical factor 
of acquired MDR in ovarian cancer cells. We first selected three transfected cell colonies 
which survived from G418 medium for at least 14 days. Then, we performed Western 
blotting and MTT assay to verify the MRP7 expression and paclitaxel resistance 
mediated by MRP7, respectively. Results showed that colony 1 exhibited the highest 
MRP7 expression level, which was comparable to the positive control HEK293/MRP7 
cells. MTT assay further demonstrated that colony 1 was resistant to paclitaxel treatment 
compared to SKOV3 cells. As a membrane transporter, subcellular localization of MRP7 
is crucial for its biological function (125). Thus, we performed immunofluorescence 
assay to determine the subcellular localization of MRP7 in SKOV3/MRP7 cells. Results 
showed that the MRP7 protein was mainly localized on cell membrane, which indicate 
functional MRP7 transporters (106). Subsequently, we performed accumulation-efflux 
assay to further verify the MRP7 efflux function in SKOV3/MRP7 cells. The results 
showed that intracellular paclitaxel concentration was significantly decreased in 
SKOV3/MRP7 cells and restored by MRP7 inhibitor cepharanthine (126).   
In summary, here we for the first time showed that overexpression of MRP7 may 
be an important mechanism in acquired resistance to paclitaxel and other 
chemotherapeutic agents in ovarian cancer. Although the MDR mechanism in ovarian 
cancer might be more complex, our finding emphasized the importance of MRP7 in the 
development of ovarian cancer drug resistance. Therefore, MRP7 level could potentially 
serve as a biomarker for MDR during chemotherapy. Additionally, establishment of this 
MRP7-overexpressing ovarian cancer cell line may facilitate the discovery of novel 
 73 
modulators to overcome acquired MDR in ovarian cancer and improve the therapeutic 





Here, we present Mrp7Pred, an online MRP7 substrate and MRP7 inhibitor 
prediction server based on machine learning techniques, which is freely available at 
http://www.mrp7pred.com. The web application has a friendly user interface and is very 
easy to use even if the user has no computational chemistry background. Therefore, 
Mrp7Pred can be used for virtual drug screening in order to discover novel MRP7 
substrates and/or inhibitors. 
4.2 Materials and methods 
Dataset establishment and curation 
The training and validation data used in this task is a manually curated non-
redundant MRP7 substrate/inhibitor/non-interactor dataset composed of experimentally 
validated substrates and inhibitors (54) and non-interactors (64). The size of our dataset is 
small due to the limited available studies regarding MRP7. Due to the fact that various 
experimental methods were used to identify MRP7 substrates or inhibitors in vitro. As a 
result, we need to determine the criteria to clearly define positive or negative data in this 
project. Here, we defined several rules to determine if a drug is an MRP7 substrate, an 
inhibitor or a non-interactor. Substrates will show reduced cytotoxicity in MRP7 
overexpressing cells, which can be reversed by MRP7 inhibitors. Examples are 
paclitaxel, vincristine and docetaxel. Inhibitors could potently reverse MRP7-mediated 
drug resistance, while not showing significant difference in IC50 values in parental and 
MRP7-overexpressing cells. Given some studies did not focus on chemotherapeutic drugs 
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but some biomolecules like LTC4, inhibiting the transportation of such molecules via 
MRP7 is also an evidence of an inhibitor, although ambiguous since substrates may also 
interfere the transportation of other substrates. For non-interactors, we chose molecules 
that do not exhibit any of the above evidence in vitro. Part of the MRP7 substrates data 
were extracted from (127). The original dataset contains 1429 anticancer drugs tested 
against 49 ABC transporters. Drug properties were represented by the correlation 
between ABC transporter mRNA expression level and sensitivity in respective cells. As 
shown in Figure 28, negative r value indicates the substrate property because the cells 
became less sensitive if there are more ABC transporter expression. The MRP7 substrates 
were then selected by r < -0.25 following a previous study (128).  
 
 
Figure 28. Sample data snippet for ABCB1 from Szakács et al., 2004.  
Model training and validation 
 The best model was trained via an automated pipeline composed of featurization, 
feature selection and parameter grid search. The compounds were represented as SMILE 
strings which were standardized by python package RDKit. Features include 1D and 2D 
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features generated by RDKit and ChemoPy (129). 1D features include constitutional 
descriptors such as molecular weight and atom counts. 2D features include connectivity 
descriptors, topology descriptors, Basak descriptors, Kappa descriptors, Burden 
descriptors, E-state descriptors, Moran autocorrelation descriptors, Geary autocorrelation 
descriptors, Moreau-Broto autocorrelation descriptors and MOE-type descriptors (129). 
Features were selected in a filter-based method. Specifically, feature pairs with high 
Pearson’s correlation were removed (Figure 29). 
 
Figure 29. Pairwise feature selection. Features with high correlation (i.e. Pearson’s 
correlation) provides similar information of the input data. Features were first converted 
into a correlation matrix then an undirected graph to remove highly correlated pairs. 
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 The validated model was then benchmarked against docking using our homology 
model. Docking results were represented in a binary pattern by setting different 
thresholds to separate interactors and non-interactors. Common metrics including 
precision, recall, F1, accuracy and ROC-AUC were then applied to compare the machine 
learning model and docking analysis results.  
In silico and in vitro validation of FDA-approved drugs as MRP7 substrates 
or modulators 
We collected 70 FDA-approved drugs (except 17 pre-clinical drugs) under 
clinical trial or on market. Both Mrp7Pred and docking analysis were implemented for 
the initial prediction. Candidates with high scores were subjected to in vitro validation 
using MTT cell viability assay in HEK293, HEK293/MRP7, SKOV3 and SKOV3/MRP7 
cells.  
Setting up online server for Mrp7Pred 
 The online web application for Mrp7Pred was deployed based on Python, Flask 
and Nginx. The backend was hosted and setup on a Digital Ocean droplet. The web 
server is freely accessible for academic use at http://www.mrp7pred.com. Currently the 
function is only available for internal use due to the pending publications. 
4.3 Results 
Model training and validation 
The pairwise feature selection results were shown in Figure 30. Dark red and 
green indicate strong feature correlation. The results showed that features with high 





Figure 30. Feature selection results. Left: Pearson’s correlation of all features before 
selection. Right: Pearson’s correlation of all features after selection. Red: Pearson’s 
correlation larger than zero. Green: Pearson’s correlation smaller than zero. 
 
 Best models were then obtained by a linear grid search over all combinations of 
model parameters. We use ROC-AUC as the major matric to determine model 
performance. Eventually, one MRP7 inhibitor prediction model and one MRP7 substrate 
prediction model was successfully established. The model performance was also 
compared with docking analysis. Results were given in Figure 31. According to the 
results, docking simulation achieved the best performance when the threshold was set to -
7.0 kcal/mol, which means if the compound got docking energy lower than -7.0 kcal/mol, 
we will consider it being an MRP7 interactor. In out held-oust test dataset, 14 interactor 
sand 21 non-interactors. Overall, both modes got reasonable results, while machine 
learning models generally need lower execution time and computational resources. 
Moreover, for the performance metrics, our Mrp7Pred model showed higher recall, F1 
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and ROC-AUC. Overall, the Mrp7Pred model showed good prediction accuracy in held-




Figure 31. Model performance and benchmark with docking analysis. Confusion matrix, 
ROC-AUC, precision, recall, F1 score and accuracy were displayed. In the middle bar 
graph, docking results were represented as dark green, green, light green, grey and white 
columns for affinity score threshold -8.0 kcal/mol, -7.5 kcal/mol, -7.0 kcal/mol,  
-6.5 kcal/mol, -6.0 kcal/mol, respectively.  
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Implement Mrp7Pred to FDA-approved drugs for MRP7 interactor 
discovery 
 Next, we implement Mrp7Pred to a series of FDA-approved anticancer drugs, in 
order to see if we could identify novel MRP7 substrates or inhibitors. We used Mrp7Pred 
for pre-screen on 70 drugs. In the end, we found 10 drugs with high substrate score and 
27 drugs with high inhibitor score (Table 5). In the subsequent in vitro test, 2 out of 10 
drugs were identified as MRP7 substrates and 4 out of 27 were identified as MRP7 
inhibitors (Figure 32, 33). MTT results of non-substrates and non-inhibitors were not 
shown here. The overall hit rate is 17.5%.  
 
Table 5. Drugs with high substrate score or inhibitor score. 
Drug Name Substrate Score 
Disulfiram 0.869 
Ixazomib Citrate 0.960 
 






Figure 32 showed the MTT results of disulfiram and ixazomib citrate in two 
MRP7-overexpression cell lines as well as their parental cell lines. Results showed that 
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both disulfiram and ixazomib citrate showed higher IC50 in MRP7-overexpressing cells 
than in parental cells. Specifically, disulfiram had resistance fold of 1.92 in HEK cells 
and 2.44 in SKOV3 cells, while ixazomib citrate had resistance fold of 8.35 in HEK cells 
and 9.64 in SKOV3 cells. Additionally, the resistance in MRP7-overexpressing cells 
could be at least partially reversed by a known MRP7 inhibitor tariquidar at 0.3 µM. In 
summary, we successfully identified two MRP7 substrates, disulfiram and ixazomib 
citrate, using Mrp7Pred. 
 
Figure 32. Cell viability assay results of disulfiram and ixazomib citrate in HEK, 
HEK/MRP7, SKOV3 and SKOV3/MRP7 cells. Solid red lines: parental cells only, red 
dashed lines: parental cells + TQR, solid green lines: MRP7-overexpressing cells only, 
green dashed lines: MRP7-overexpressing cells + TQR. RF: resistance fold, calculated by 
the IC50 in resistant cells divided by IC50 in parental cells. TQR: tariquidar. Data are 
expressed as mean ± SD derived from three independent experiments.  
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 Figure 33 showed the MTT results of predicted MRP7 inhibitors in SKOV3 and 
SKOV3/MRP7 cells. To validate predicted inhibitors, we treated cells with a combination 
of one of the four predicted drugs and paclitaxel. Based on Figure 33, the four predicted 
inhibitors could at least partially reverse MRP7-mediated paclitaxel-resistance in 
SKOV3/MRP7 cells. Specifically, 10 µM selonsertib reduced the resistance fold from 8.8 
to 3.7, vatalinib reduced the resistance fold from 8.8 to 3.9, IWR-1-endo reduced the 
resistance fold from 8.8 to 5.7, berzosertib reduced the resistance fold from 8.8 to 5.7. 
Till now, we have confirmed the predictability of our Mrp7Pred model.  
 
Figure 33. Validating predicted MRP7 inhibitors. Cell viability was represented in 
percentage. Red solid line: SKOV3, blue solid line: SKOV3/MRP7, red dashed line: 
SKOV3 + predicted inhibitor, blue dashed line: SKOV3/MRP7 + predicted inhibitor. RF: 
resistance fold, calculated by the IC50 in resistant cells divided by IC50 in parental cells. 
Data are expressed as mean ± SD derived from three independent experiments. 
 
Mrp7Pred online web server 
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To extend the usability of our Mrp7Pred model, we deployed the substrate and 
inhibitor model to a web server for users, which is freely available at 
http://www.mrp7pred.com. Figure 34 displayed an overview workflow of the web server. 
In brief, the user could upload their own compound dataset which was formatted based 
on our instruction.  
 
Figure 34. An overview of the workflow of the Mrp7Pred web server. 
 
The graphic user interface is straightforward and easy to use. There are 5 sections, 
and we will be briefly introducing each section here.  
Figure 35 showed the title page and side navigation bar. From here, user could be 
directly guided to the prediction section or to view other sections. Figure 36 showed the 
section where basic information of MRP7 was introduced to the users.  Figure 37 showed 
the instruction page, where users can find guidance in data preparation, model 
implementation and result interpretation. Figure 38 showed the section of sample data, 
where users can download our sample data to test the server. Figure 39 showed the 
section where users can upload their prepared data and run the prediction. Once the users 
click “run”, a waiting page will pop up and models start running. The model will first 
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featurize all compounds then make prediction. The execution time varies depend on the 
complexity of chemical structures and data size. On average, the execution time is 10-15 
seconds per compound. Once the prediction finishes, the users will see a result page 
similar to Figure 41. The compound name, 2D chemical structure, SMILES string, 
molecular weight, substrate score and inhibitor score will be displayed. Compounds 
failed in featurization will not appear in the report. Users can then click “Save as PDF” to 
download the PDF version of the report. 
 





Figure 36. Section 2:basic information of MRP7. 
 
 

















Figure 41. Prediction report.  
 
4.4 Discussion 
 Here, we for the first time established a machine learning model for MRP7 
substrate and inhibitor prediction, which we believe will be beneficial to the field of 
cancer drug resistance. By using Mrp7Pred, researchers could accelerate the progress of 
MRP7 inhibitor discovery and lower the cost. It is worth noting that although the 
machine learning model could quickly provide predictions for MRP7 inhibitors and 
substrates, the interpretability of this model still needs improvement. Unlike docking 
analysis, where the potential molecular interactions that may contribute to the binding are 
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clearly illustrated, our model cannot provide information regarding factors that may 
contribute to a positive prediction. Although we can use more complex model, such as 
attention-based sequential models to show important groups or structures, it is more 
feasible to deploy a simpler model as an online server considering the computational 
resources.  
LIMITATIONS 
 Identifying drug target interactions greatly reduced the candidates for the search of 
potential medications (130). As a result, drug-target interaction screening is always the 
first step in drug discovery (131). Based on the “no free lunch theorem”, a successful 
machine learning model needs reasonable data to make reasonable predictions (132). 
Moreover, in drug-target interaction prediction, the acquisition of negative data can be 
challenging since it is hard to determine if a drug is not interacting with the protein of 
interest. Currently, a large number of supervised models regard unlabeled data or those 
without experimental results as negative, which could be erroneous (133). In this study, 
we carefully picked our negative data. Instead of using those without clear results, we 
chose compounds that particularly tested for MRP7 interaction but got negative results. 
For example, a negative compound would have similar cytotoxicity in both parental and 
resistant cell lines. Additionally, negative compounds will not significantly alter the drug 
resistance profile of resistant cells. Our negative data is more reliable than simply 
unlabeled data, however, considering the complexity of cell system, there might be 
multiple pathways including MRP7 overexpression that affect the drug resistance (134). 
Moreover, researchers from different research groups may have different criteria in 
defining MDR in cancer cells, which could lead to inconsistency in drug-target 
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interactions. As a result, it is necessary to unify the criteria for defining the multidrug 
resistance in cancer cells so that more meaningful discoveries could be obtained via in 
silico, in vitro or in vivo approaches.  
 Since MRP7 was first discovered in 2001 and is one of the most recent discovered 
ABC transporters. Due to the limitation of proper cell models, not so many studies are 
available regarding the modulation of MRP7-mediated drug resistance. As a result, we 
are not able to obtain much data to train a machine learning model. Since the 
performance of a machine learning model heavily relies on the quality of data, less data 
may cause the model to underfit all of the parameters which will deteriorate the 
prediction accuracy (135). This is also an important factor when selecting proper models. 
In this study, we decided to use simpler models with fewer parameters given the limited 
amount of data. Finally, small size data may lead to bias since we cannot guarantee that 
our training data accurately represent the population. Thus, it is crucial to expand the 
dataset size. 
 Currently, our online webserver performs featurization and prediction once 
received the input data prepared by users. However, the featurization is time-consuming. 
To accelerate the whole process, it is important for us to further optimize the algorithm to 
improve the prediction efficiency. We do provide users with an alternative: by using the 
local version which needs users to build the Mrp7Pred from scratch. The local version 
avoids Internet traffic and the limitation in computational resources of the web server. In 
the future, we could implement the model using compound embeddings which could be 




Since the discovery of P-glycoprotein and its role in cancer drug resistance, 
extensive studies have been made to design potent reversal agents in order to overcome 
drug resistance and increase the therapeutic efficacy (137). However, after the failure of 
several ABC transporter inhibitors in clinical trials, such as tariquidar, researchers are 
now turning to different directions in this field (20) including developing high-throughput 
methods to reduce the cost of pre-screening so that we could find candidates from a 
larger pool (138). Computational models were boosted thanks to the bloom of modern 
machine learning techniques. Nowadays, researchers have more and more choice in 
performed computational compound screening such as traditional structure-based or 
ligand-based pharmacophore screening (139), probability-based Bayesian models (140), 
conventional supervised models (28) or more complex neural network-based deep 
learning models (141). In this work, we focused more on traditional supervised learning 
models including SVM, random forest, gradient boost or simply neural networks. In 
future works, more complex and interpretable models could be implemented in order to 
expand the predictability of our model as well as extend the use cases (142).  
Cancer is still one of the worldwide leading cause of death, and the drug 
resistance in recurring cancer further reduced the patients’ survival rate (143). As a result, 
it is still of great importance to develop potent and selective inhibitors to overcome 
cancer drug resistance by targeting ABC transporters especially MRP7, which has been 
found to mediate the resistance of taxanes and vinca alkaloids. Our work not only expand 
our understanding in MRP7-mediated cancer drug resistance, but also provided an 
accessible method to predict novel MRP7 substrates or inhibitors, which could then be 
 92 
validated in our ovarian cancer MRP7 cell line. In summary, this work greatly extends 
the study regarding MRP7-mediated cancer drug resistance, and hopefully could provide 
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